var title_f3_33_3600="ECG ventriculophasic sinus arrhythmia";
var content_f3_33_3600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Electrocardiographic (ECG) rhythm strip demonstrating ventriculophasic sinus arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 113px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complete atrioventricular (AV) block is seen as evidenced by the AV dissociation. A junctional escape rhythm sets the ventricular rate at 45 bpm. The PP intervals vary because of ventriculophasic sinus arrhythmia; this is defined when the PP interval that includes a QRS is shorter than a PP interval that excludes a QRS. The QRS generates a strong enough pulse to activate the carotid sinus mechanism which slows the subsequent PP interval. With permission of Dr. Frank Yanowitz, University of Utah, from the Alan E. Lindsey ECG Learning Center in Cyberspace (file://medstat.med.utah.edu/kw/ecg)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3600=[""].join("\n");
var outline_f3_33_3600=null;
var title_f3_33_3601="Exanthematous drug eruption - Back";
var content_f3_33_3601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exanthematous (morbilliform) drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Profuse eruption of macules and papules on the back of a patient with exanthematous drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3601=[""].join("\n");
var outline_f3_33_3601=null;
var title_f3_33_3602="Mixed gonadal dysgenesis";
var content_f3_33_3602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mixed gonadal dysgenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3602=[""].join("\n");
var outline_f3_33_3602=null;
var title_f3_33_3603="Pathophysiology of cardiogenic shock";
var content_f3_33_3603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of cardiogenic shock",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 490px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Current concept of CS pathophysiology. The classic shock spiral (bold spiral), induced by left ventricular (LV) dysfunction leading to death by further promotion of ischemia and progressive LV dysfunction if not interrupted by treatment, is shown. The shock spiral is further negatively influenced by (i) systolic dysfunction with decreased cardiac output and stroke volume leading to peripheral impaired perfusion and hypotension; (ii) diastolic dysfunction leading to hypoxemia owing to pulmonary congestion; and (iii) promotion of the systemic inflammation response syndrome (SIRS) by endothelial and inducible nitric oxide synthase (eNOS and iNOS), interleukin-6 (IL-6), tumour necrosis factor-&alpha; (TNF-&alpha;) leading to paradoxical reduced systemic vascular resistance (SVR). Adapted according to Reynolds &amp; Hochman (2008). The pathophysiological concept is expanded by bleeding complications and subsequent transfusions, which both also negatively contribute to inflammation and subsequently the shock spiral. Treatment options such as (i) reperfusion by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); (ii) mechanical support by intra-aortic balloon pumping (IABP) or left ventricular assist devices (LVADs); and (iii) inotropes or vasopressors to reverse the shock spiral are shown in green. Potential drawbacks of therapeutic interventions including bleeding complications and influence on SIRS are shown in red.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Thiele H, Allam B, Chatellier G, et al. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J 2010; 31:1828, by permission of the European Society of Cardiology. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3603=[""].join("\n");
var outline_f3_33_3603=null;
var title_f3_33_3604="Ciclesonide (nasal): Pediatric drug information";
var content_f3_33_3604=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclesonide (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=see_link\">",
"    see \"Ciclesonide (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/37/27221?source=see_link\">",
"    see \"Ciclesonide (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;;",
"     </li>",
"     <li>",
"      Zetonna&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F11162804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Intranasal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F11162811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=see_link\">",
"      see \"Ciclesonide (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal:",
"     <b>",
"      Note:",
"     </b>",
"     One spray delivers 50 mcg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perennial allergic rhinitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-11 years: Limited data available: 100 or 200 mcg once daily delivered as 50 mcg (1 spray) or 100 mg (2 sprays)",
"     <b>",
"      per nostril",
"     </b>",
"     (Berger, 2008; Kim, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years, Adolescents, and Adults: 200 mcg once daily delivered as 100 mcg  (2 sprays) per nostril; maximum dose: 200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults: 200 mcg once daily delivered as 100 mcg (2 sprays) per nostril; maximum dose: 200 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8002800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetonna&trade;: 37 mcg/inhalation (6.1 g) [contains ethanol; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnaris&reg;: 50 mcg/inhalation (12.5 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8002706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11162812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Intranasal: Shake bottle gently before using. Prime pump prior to first use (press 8 times until fine mist appears) or if spray has not been used in 4 consecutive days (press 1 time or until a fine mist appears). Clear nasal passages by blowing nose prior to use. While keeping bottle upright and closing off the other nostril, breathe in through nose and press pump to release spray. Avoid spraying directly onto the nasal septum. Do not spray into eyes. Rinse nasal applicator with warm water to clean. Discard after the \"discard by\" date or 120 sprays, even if bottle is not completely empty.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11162809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F), excursions to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) permitted; do not freeze; use within 4 months after opening aluminum pouch.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11162805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Management of seasonal allergic rhinitis (FDA approved in ages &ge;6 years and adults); management of perennial allergic rhinitis (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8002723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dysphonia, fever (children), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Back pain, muscle strain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchitis, cough, epistaxis, hoarseness, nasal congestion, nasal discomfort, nasal septum disorder, nasopharyngitis, paradoxical bronchospasm, pharyngitis, pharyngolaryngeal pain, pneumonia, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: ALT increased, angioedema (with swelling of lip/pharynx/tongue), bruising, candidiasis (nasal/pharyngeal), cataract, chest discomfort, dizziness, dry throat, dysgeusia, dyspepsia, GGT increased, growth suppression, intraocular pressure increased, nasal ulcer, palpitation, rash, rhinorrhea, throat irritation, WBC increased, weight gain, wound healing impaired, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11162806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciclesonide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13134478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use ciclesonide with extreme caution in patients with respiratory tuberculosis, untreated bacterial, fungal, systemic viral or parasitic infections, or ocular herpes simplex. Localized",
"     <i>",
"      Candida",
"     </i>",
"     infections of the nose and pharynx have been reported rarely; interruption of therapy may be necessary while antifungal therapy is employed. Corticosteroids impair wound healing; avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma; allow healing to occur before use. Use of nasal ciclesonide in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Rare cases of immediate hypersensitivity reactions, nasal septum perforation, increased IOP, glaucoma, or cataracts may occur with intranasal corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11162807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA suppression or hypercorticism (Cushing's syndrome) may occur with use of higher than recommended doses or at typical doses in susceptible patients. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use, with stress, or when converting from systemic to topical corticosteroid therapy; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Epistaxis may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8002734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8002735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8043197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8043198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported following subcutaneous administration of ciclesonide in animal reproduction studies. The extent of intranasal absorption of ciclesonide systemically is low but variable. Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy. Intranasal corticosteroids may be used in the treatment of rhinitis during pregnancy (Wallace, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13134488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucus membranes for signs of fungal infection; monitor growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13134486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciclesonide is a prodrug that is hydrolyzed to the active metabolite des-ciclesonide which has a high affinity for the glucocorticoid receptor where it acts to control the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13134487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 24-48 hours; further improvement observed over 1-2 weeks in seasonal allergic rhinitis or 5 weeks in perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11162810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ciclesonide hydrolyzed to active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: &lt;1%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13134489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/37/27221?source=see_link\">",
"      see \"Ciclesonide (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Full response to this medication may not be seen for 2-5 weeks. Use regularly. Do not stop treatment, even if feeling better. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay. Report sore mouth or mouth lesions, persistent headache, or nosebleeds to physician; carefully read and follow the patient instructions for use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berger WE, Nayak A, Lanier BQ, et al, &ldquo;Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children with Allergic Rhinitis,&rdquo;",
"      <i>",
"       Pediatr Asthma Allergy Immunol",
"      </i>",
"      , 2008, 21:73-82.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim K, Weiswasser M, Nave R, et al, &ldquo;Safety of Once-Daily Ciclesonide Nasal Spray in Children 2-5 Years of Age with Perennial Allergic Rhinitis,&rdquo;",
"      <i>",
"       Pediatr Asthma Allergy Immunol",
"      </i>",
"      , 2007, 20(4):229-42.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16758 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3604=[""].join("\n");
var outline_f3_33_3604=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002705\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162804\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162811\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002800\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002706\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162812\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162809\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162805\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002723\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162806\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134478\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162807\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134488\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134486\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134487\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11162810\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134489\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/26/22949?source=related_link\">",
"      Ciclesonide (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3605="Thioguanine: Patient drug information";
var content_f3_33_3605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Thioguanine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     see \"Thioguanine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/51/35637?source=see_link\">",
"     see \"Thioguanine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tabloid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lanvis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a type of leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703020",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thioguanine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697144",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a thiopurine methyltransferase deficiency, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC drugs, vitamins, natural products, or herbals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Severe diarrhea",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698972",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2800807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug for more than 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11338 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3605=[""].join("\n");
var outline_f3_33_3605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226912\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226913\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028421\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028420\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028425\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028426\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028428\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028423\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028424\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028429\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028430\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=related_link\">",
"      Thioguanine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/51/35637?source=related_link\">",
"      Thioguanine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3606="Ketorolac (systemic): Patient drug information";
var content_f3_33_3606=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketorolac (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=see_link\">",
"     see \"Ketorolac (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=see_link\">",
"     see \"Ketorolac (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8345791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketorolac Injectable&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Tablet;",
"     </li>",
"     <li>",
"      Ketorolac Tromethamine Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Ketorolac;",
"     </li>",
"     <li>",
"      Nu-Ketorolac;",
"     </li>",
"     <li>",
"      Toradol&reg;;",
"     </li>",
"     <li>",
"      Toradol&reg; IM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is only to be used for 5 days total. It is for very bad, short-term pain. It may cause unsafe side effects if taken more than 5 days. Let your doctor know if you have ulcer disease, kidney disease, a chance of bleeding or any active bleeding, allergies to ketorolac, aspirin, or any other pain drugs. Do not take if you are pregnant or breast-feeding. Tell your doctor if you are 65 years of age or older or weigh less than 110 pounds (50 kilograms).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketorolac tromethamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, bleeding problems, hole in the GI (gastrointestinal) tract, recent GI bleeding, very bad kidney disease, ulcer disease, or use before surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696936",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 5 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older or weigh less than 110 pound, you may need a smaller dose. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12236 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3606=[""].join("\n");
var outline_f3_33_3606=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029846\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029848\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029847\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029852\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029853\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029855\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029850\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029851\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029856\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029857\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3607="Clinical assessment and diagnosis of hypovolemia (dehydration) in children";
var content_f3_33_3607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Michael J Somers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3607/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/33/3607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid therapy is intended to maintain the normal volume and composition of body fluids and, if needed, to correct any existing abnormalities. In children, the most common abnormality is hypovolemia.",
"   </p>",
"   <p>",
"    Volume depletion occurs when fluid is lost from the extracellular space at a rate that exceeds intake. The most common sites for extracellular fluid loss are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal tract (eg, diarrhea, vomiting, bleeding)",
"     </li>",
"     <li>",
"      Skin (eg, fever, burns)",
"     </li>",
"     <li>",
"      Urine (eg, glucosuria, diuretic therapy, diabetes insipidus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, hypovolemia can result from prolonged inadequate intake without excessive losses.",
"   </p>",
"   <p>",
"    Children are at increased risk for hypovolemia for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a higher frequency of gastroenteritis (diarrhea and vomiting) in children compared to adults.",
"     </li>",
"     <li>",
"      Children, especially young children, have a higher surface area-to-volume ratio with proportionally higher insensible losses that are accentuated in disease states (eg, fever or burns).",
"     </li>",
"     <li>",
"      Young children are unable to communicate their need for fluids or cannot independently access fluids to replenish volume losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volume depletion reduces the effective circulating volume (ECV), compromising tissue and organ perfusion. If severe hypovolemia is not corrected in a timely fashion, ischemic end-organ damage occurs, leading to serious morbidity and, in patients in shock, death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical assessment and diagnosis of hypovolemia will be reviewed here. Repletion therapy for hypovolemia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VOLUME DEPLETION VERSUS DEHYDRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms volume depletion (hypovolemia) and dehydration are often used interchangeably. However, these terms differentiate physiologic conditions resulting from different types of fluid loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume depletion refers to any condition in which the effective circulating volume is reduced. It can be produced by salt and water loss (as with vomiting, diarrhea, diuretics, bleeding, or third space sequestration) or by water loss alone (as with insensible water losses or diabetes insipidus).",
"     </li>",
"     <li>",
"      Dehydration refers to water loss alone. The clinical manifestation of dehydration is often",
"      <strong>",
"       hypernatremia",
"      </strong>",
"      . The elevation in serum sodium concentration, and therefore serum osmolality, pulls water out of the cells into the extracellular fluid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Type of fluid lost'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, much of the clinical literature does not differentiate between the two terms and uses them interchangeably. Thus, we will follow this convention and use the terms hypovolemia, volume depletion, and dehydration interchangeably as referring to all types of fluid deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing a child with hypovolemia, the clinician needs to address two issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of extracellular fluid volume depletion",
"     </li>",
"     <li>",
"      The type of fluid lost (extracellular fluid or both intracellular and extracellular fluid)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Degree of dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid repletion guidelines for children with gastroenteritis by the American Academy of Pediatrics, Centers for Disease Control, and the World Health Organization are based upon the degree of volume depletion. As a result, it is important to be as accurate as possible when assessing the degree of dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Severe hypovolemia requires rapid isotonic fluid resuscitation, although oral rehydration may be sufficient for mild to moderate hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=see_link\">",
"     \"Prevention and treatment of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume depletion is most objectively measured as a change in weight from baseline. Acute loss of body weight reflects the loss of fluid, not lean body mass; thus, a 2 kg weight loss should reflect the loss of two liters of fluid.",
"   </p>",
"   <p>",
"    In most cases, however, a previous recent weight is not available. As a result, a number of findings on physical examination coupled with the pertinent clinical history are used to help assess the severity of hypovolemia. These findings include the child's pulse, blood pressure, skin turgor, systemic signs such as increased thirst or lethargy, and changes in urine output (",
"    <a class=\"graphic graphic_table graphicRef76198 \" href=\"UTD.htm?13/5/13404\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild dehydration (3 to 5 percent volume loss) &ndash; A history of fluid losses may be the sole finding, as clinical signs may be absent or minimal. Such patients may have a reduction in urine output, but this may not be appreciated.",
"     </li>",
"     <li>",
"      Moderate dehydration (6 to 9 percent volume loss) &ndash; Signs and symptoms are now apparent and can include the following: tachycardia, orthostatic falls in blood pressure, especially with orthostatic changes, decreased skin turgor, dry mucous membranes, irritability, decreased peripheral perfusion with a delay in capillary refill between two and three seconds, and deep respirations with or without an increase in respiratory rate. There may be a history of reduction in urine output and decreased tearing and, in infants, an open fontanelle will be sunken on physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a systematic review of the literature, the most useful clinical signs that predicted 5 percent hypovolemia in children were delayed capillary refill time, reduced skin turgor, and deep respirations with or without an increase in absolute respiratory rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/4\">",
"     4",
"    </a>",
"    ]. A combination of signs and symptoms was better than an individual finding at predicting hypovolemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe dehydration (&ge;10 percent volume loss) &ndash; Such children typically have a near-shock presentation as manifested by hypotension, decreased peripheral perfusion with a capillary refill of greater than three seconds, cool and mottled extremities, lethargy, and deep respirations with an increase in rate. Severe hypovolemia requires immediate aggressive isotonic fluid resuscitation to restore the ECV and prevent ischemic tissue injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type of fluid lost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical assessment for volume depletion outlined above is most pertinent to states of extracellular fluid losses as is seen with gastroenteritis. In children with gastrointestinal illness, the fluid loss usually is isosmotic and is mostly from the extracellular space. The diarrheal isotonic fluid typically has a sodium plus potassium concentration between 40 and 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], and organic solutes, such as urea and fermentation products, make up the remaining osmoles.",
"   </p>",
"   <p>",
"    In contrast to diarrheal fluid loss, insensible fluid losses and losses in states of urinary concentrating defects (diabetes insipidus) represent water loss alone and, as noted above, result in hypernatremia. The associated increase in serum osmolality from the hypernatremia pulls water out of the cells, which initially minimizes the degree of extracellular fluid volume loss. This also minimizes some of the physical findings that are associated with isotonic extracellular fluid loss.",
"   </p>",
"   <p>",
"    These considerations also apply to children with diabetes mellitus with significant hyperglycemia, which causes a hyperosmolar state that pulls water out of the cells, thereby minimizing the degree of extracellular hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing often reveals normal electrolytes and acid base balance in children with mild dehydration. As a result, measurement of serum electrolytes is typically limited to children who require intravenous fluid repletion. These children are more severely volume depleted and are, therefore, at greater risk for electrolyte and acid-base abnormalities. With ongoing volume depletion, renal salt and water avidity increases and spot urine sodium concentrations d25",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    should ensue.",
"   </p>",
"   <p>",
"    Laboratory testing is less useful for assessing the degree of volume depletion. This was illustrated in the systematic review of the literature cited above and a prospective study of children who required intravenous fluid for volume repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum bicarbonate was the most useful laboratory test to assess degree of dehydration in children. A value below 17",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      differentiated children with moderate and severe hypovolemia from those with mild hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/4,8\">",
"       4,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The blood urea nitrogen (BUN) rose with increasing severity of hypovolemia, reflecting the decline in glomerular filtration rate and increase in sodium and water reabsorption and urea recycling. The sensitivity of BUN elevation was not sufficient to be clinically useful, however, since it may be increased by other factors such as bleeding or catabolic tissue breakdown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum sodium concentration is determined by the ratio between sodium salts and water in the extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Thus, the serum sodium concentration in a child with hypovolemia varies with the relative loss of solute to water. Changes in the serum sodium concentration play an important role in deciding the type and speed of fluid repletion therapy, especially in children with severe hyponatremia or hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia &ndash; The development of hyponatremia (serum sodium less than 130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      reflects net solute loss in excess of water loss. This does not occur directly, as losses such as diarrhea are not hypertonic to plasma. Rather, solute and water are lost in proportion, and water is taken in and retained (because hypovolemia-induced secretion of antidiuretic hormone limits water excretion), lowering the serum sodium concentration (see below).",
"     </li>",
"     <li>",
"      Isonatremia &ndash; A serum sodium between 130 and 150",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      reflects isonatremia. In this setting, solute is lost in proportion to water loss. As an example, in patients with secretory diarrhea (eg, Vibrio cholerae gastroenteritis), the solute concentration of the diarrheal fluid is similar to the plasma solute concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/6,10\">",
"       6,10",
"      </a>",
"      ], thus the serum sodium concentration is not affected.",
"     </li>",
"     <li>",
"      Hypernatremia &ndash; The development of hypernatremia (serum sodium greater than 150",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      reflects water loss in excess of solute loss. In children with viral gastroenteritis (eg, rotavirus), the solute concentration of the diarrheal fluid typically ranges between 40 and 100",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      Loss of this relatively dilute fluid will tend to induce hypernatremia if there is no concomitant water intake [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/5\">",
"       5",
"      </a>",
"      ]. This entity is referred to as hypernatremic dehydration [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever or tachypnea often accompany pediatric illness associated with hypovolemia, resulting in increased insensible water losses, especially in young children. Water is, again, lost in excess of solute, contributing to an increase in sodium concentration. A similar effect is seen with dilute urinary losses in children with diabetes insipidus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Secretion of ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the composition of the fluid that is lost is the initial factor that affects the serum sodium, subsequent antidiuretic hormone (ADH) release also may be important. ADH secretion promotes the retention of free water in the distal nephron and is stimulated by hyperosmolality or moderate to severe hypovolemia (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ). In children with hypernatremia and associated hyperosmolality, ADH secretion and avid water reabsorption by the kidney decreases urinary water loss and tends to prevent a further increase in serum sodium. In children with hypovolemia who are not hypernatremic, ADH-induced decreases in water loss can lead to hyponatremia if water intake is maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prior fluid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to seeking medical treatment, replacement therapy using oral fluids with varying concentrations of sodium may have been provided to the patient. Most often, such fluid replacement is hypotonic and will lower sodium concentration due to the net loss of solute and ADH-induced decreases in urinary water loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either hypokalemia or hyperkalemia can occur in hypovolemic patients. Hypokalemia is more common, as children with gastroenteritis lose potassium in diarrheal stool. However, the serum potassium concentration may be higher than expected or even elevated if a marked acidosis is present. In this setting, excess hydrogen ions enter the cells to be buffered, and electroneutrality is maintained in part by potassium movement from the cells into the extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/13\">",
"     13",
"    </a>",
"    ]. This effect of pH does not appear to be as important with lactic acidosis or ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/14\">",
"     14",
"    </a>",
"    ]. Hyperkalemia can occur in these disorders but often arises because of other factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of hypovolemia upon potassium balance are reversed with correction of the acidosis, leading to a fall in the serum potassium concentration to a degree consistent with the true potassium deficit. In children with borderline potassium reserves, this fall can result in hypokalemic symptoms, such as muscle weakness, intestinal ileus, flattening of the T waves and the development of U waves on electrocardiogram, and potentially lethal arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, physicians managing children with significant hypovolemia must be prepared to recognize and treat acute hypokalemia, especially if the serum potassium is borderline low or depressed in a child with acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, a low serum bicarbonate concentration (less than 17",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    may be useful in assessing the degree of hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3607/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The low serum bicarbonate in hypovolemia almost always represents metabolic acidosis. In children with gastroenteritis, the acidosis is because of the loss of bicarbonate in the stool.",
"   </p>",
"   <p>",
"    Other causes of acidosis associated with diarrheal losses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased acid production from shock (lactic acidosis) or from enhanced fat breakdown (eg, starvation or fasting ketosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link\">",
"       \"Alcoholic and fasting ketoacidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Decreased acid excretion by the kidney caused by a reduction in renal perfusion due to a reduction of effective circulatory perfusion due to hypovolemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The acid-base status may be different in children with vomiting rather than diarrheal losses. In this setting, the loss of hydrochloric acid in gastric secretions will lead to metabolic alkalosis and an elevated serum bicarbonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urine sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response of the kidney to volume depletion is to conserve sodium and water to restore the ECV. In hypovolemia, the urine sodium concentration in a random void should be less than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and may actually become non-detectable.",
"   </p>",
"   <p>",
"    Values higher than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    do not necessarily exclude relative hypovolemia or renal sodium avidity, as there also may be a high rate of water reabsorption. In this setting, both sodium excretion and urine volume are low, but the urine sodium concentration is higher than expected",
"    <span class=\"nowrap\">",
"     (&gt;25mEq/L)",
"    </span>",
"    because of the high rate of water reabsorption from the renal filtrate.",
"   </p>",
"   <p>",
"    The effect of differences in water reabsorption and urine concentration can be eliminated by calculating the fractional excretion of sodium (FENa) in standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for SI (international units) , (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The FENa is most useful in patients with an increasing serum creatinine, decreased urinary volume, and concern regarding an evolving acute renal failure. In that setting, a FENa &lt;1 percent suggests volume depletion or a \"pre-renal\" state that should respond to fluid resuscitation. A value greater than 2 percent suggests intrinsic renal impairment.",
"   </p>",
"   <p>",
"    Use of the FENa in other clinical scenarios is fraught with potential error because the value for FENa that defines hypovolemia varies inversely with the glomerular filtration rate. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urine osmolality and specific gravity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hypovolemic states, the urine should be concentrated with an osmolality exceeding 450",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    However, this response may not be seen if concentrating ability is impaired by renal disease, an osmotic diuresis, the administration of diuretics, or central or nephrogenic diabetes insipidus. Thus, a high urine osmolality is consistent with hypovolemia, but a relatively isosmotic value does not exclude hypovolemia.",
"   </p>",
"   <p>",
"    Measuring the specific gravity also can assess urinary concentration. This test, however, is less accurate than the osmolality, as it is dependent upon the size as well as the number of solute particles in the urine. As a result, it should be used only if the osmolality cannot be measured; a value above 1.015 is suggestive of a concentrated urine, as is usually seen with hypovolemia. This does not apply to diabetic ketoacidosis, as glucose raises the specific gravity without affecting the urine osmolality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H413987#H413987\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       \"Patient information: Dehydration (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion occurs when fluid is lost from the extracellular space at a rate that exceeds intake. Extracellular fluid losses commonly occur from the gastrointestinal tract (eg, diarrhea, vomiting, and bleeding), skin (eg, fever and burns), and urine (eg, diuretic therapy and diabetes insipidus).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children are at increased risk for hypovolemia compared to adults because they have a higher incidence of gastroenteritis, higher insensible loss due to a greater surface area-to-volume ratio, and may not be able to independently access fluids to replenish their losses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a child with hypovolemia includes determining the degree extracellular fluid depletion and the type of fluid lost, which may affect the serum concentration of electrolytes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volume depletion is most objectively measured as a change in weight from baseline. However, in most cases, a previous recent weight is not available. As a result, a number of findings on physical examination as well as pertinent history are used to help assess the severity of hypovolemia; mild (3 to 5 percent volume loss), moderate (6 to 9 percent volume loss), and severe (&ge;10 percent volume loss). These findings include the pulse, blood pressure, skin turgor, systemic signs, and changes in urine output (",
"      <a class=\"graphic graphic_table graphicRef76198 \" href=\"UTD.htm?13/5/13404\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Laboratory testing can detect associated electrolyte and acid-base abnormalities, and impaired urinary concentration.",
"     </li>",
"     <li>",
"      Serum sodium concentration varies with the relative loss of solute to water, which is affected by the sodium and potassium concentration of the fluid loss, secretion of antidiuretic hormone (ADH), and the amount of sodium and potassium concentration of replacement fluid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with gastroenteritis, hypokalemia is common due to loss of potassium in diarrheal stool. However, serum potassium concentration may be higher than expected because of acidosis, which promotes intracellular potassium movement to the extracellular fluid. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serum potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum bicarbonate levels &le;17",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      differentiated children with moderate to severe hypovolemia from those with mild hypovolemia. In children with gastroenteritis, the low serum bicarbonate represents metabolic acidosis usually due to loss of bicarbonate in the stool. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serum bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with hypovolemia, urine sodium concentration is usually less than 25",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      and urinary osmolality greater than 450",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Urine sodium'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Urine osmolality and specific gravity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/1\">",
"      Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med 1997; 127:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/2\">",
"      Practice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Pediatrics 1996; 97:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/3\">",
"      King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/4\">",
"      Steiner MJ, DeWalt DA, Byerley JS. Is this child dehydrated? JAMA 2004; 291:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/5\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/6\">",
"      Shiau YF, Feldman GM, Resnick MA, Coff PM. Stool electrolyte and osmolality measurements in the evaluation of diarrheal disorders. Ann Intern Med 1985; 102:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/7\">",
"      Teree TM, Mirabal-Font E, Ortiz A, Wallace WM. Stool losses and acidosis in diarrheal disease of infancy. Pediatrics 1965; 36:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/8\">",
"      Vega RM, Avner JR. A prospective study of the usefulness of clinical and laboratory parameters for predicting percentage of dehydration in children. Pediatr Emerg Care 1997; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/9\">",
"      EDELMAN IS, LEIBMAN J, O'MEARA MP, BIRKENFELD LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/10\">",
"      Santosham M, Greenough WB 3rd. Oral rehydration therapy: a global perspective. J Pediatr 1991; 118:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/11\">",
"      Bruck E, Abal G, Aceto T Jr. Pathogenesis and pathophysiology of hypertonic dehydration with diarrhea. A clinical study of 59 infants with observations of respiratory and renal water metabolism. Am J Dis Child 1968; 115:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/12\">",
"      Finberg L. Hypernatremic (hypertonic) dehydration in infants. N Engl J Med 1973; 289:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/13\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/14\">",
"      Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3607/abstract/15\">",
"      Brem AS. Disorders of potassium homeostasis. Pediatr Clin North Am 1990; 37:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6142 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3607=[""].join("\n");
var outline_f3_33_3607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VOLUME DEPLETION VERSUS DEHYDRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Degree of dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type of fluid lost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Secretion of ADH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prior fluid replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urine sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine osmolality and specific gravity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6142|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13404\" title=\"table 1\">",
"      Pediatric signs of dehydration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=related_link\">",
"      Prevention and treatment of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3608="Laboratory assessment of thyroid function";
var content_f3_33_3608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laboratory assessment of thyroid function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3608/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3608/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3608/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/33/3608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secretion of the thyroid hormones T4 (thyroxine) and T3 (triiodothyronine) is regulated by pituitary thyrotropin (TSH) (",
"    <a class=\"graphic graphic_figure graphicRef75399 \" href=\"UTD.htm?10/24/10629\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"     figure 2",
"    </a>",
"    ). TSH secretion, in turn, is controlled through negative feedback by thyroid hormones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .) There is a negative log-linear relationship between serum free T4 and TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/1\">",
"     1",
"    </a>",
"    ]. This means that very small changes in serum free T4 concentrations induce very large reciprocal changes in serum TSH concentrations. As a result, thyroid function is best assessed by measuring serum TSH, assuming steady state conditions and the absence of pituitary or hypothalamic disease. Nevertheless, direct measurement of serum thyroid hormone levels is still important in many patients, since it may be difficult in some patients to be certain about the state of pituitary and hypothalamic function.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of thyroid function testing. More detailed discussions of serum TSH and free thyroid hormone measurements, abnormalities in thyroid hormone binding proteins, and the effects of drugs and nonthyroidal illness on thyroid function tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=see_link\">",
"     \"Drug interactions with thyroid hormones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS USED TO ASSESS THYROID FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function is assessed by one or more of the following tests (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum TSH concentration",
"     </li>",
"     <li>",
"      Serum total T4 concentration",
"     </li>",
"     <li>",
"      Serum total T3 concentration",
"     </li>",
"     <li>",
"      Serum free T4 (or T3) concentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serum TSH concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation TSH radioimmunoassays had detection limits of about 1",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    Since the normal range for serum TSH is about 0.4 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    these assays were useful for the diagnosis of primary hypothyroidism (in which serum TSH concentrations are appropriately elevated), but were not sufficiently sensitive to distinguish between normal serum TSH concentrations and the low serum TSH concentrations present in most patients with hyperthyroidism.",
"   </p>",
"   <p>",
"    Second generation TSH immunometric assays have detection limits of about 0.1",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    Since this detection limit is just below the normal range for TSH of about 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    these assays can be used as screening tests to distinguish hyperthyroidism from euthyroidism and hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/2\">",
"     2",
"    </a>",
"    ]. However, since the range of subnormal TSH measurement is very limited, values near or at the detection limit do not distinguish the degree of hyperthyroidism, and poor quality control in many laboratories can lead to erroneous values [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Third generation TSH chemiluminometric assays, currently in wide use, have detection limits of about 0.01",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    They can therefore provide detectable TSH measurements even in mild hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/4\">",
"     4",
"    </a>",
"    ]. Because of the considerably lower detection limit, even with poor quality control, serum TSH values in patients with overt hyperthyroidism are easily distinguished from those in euthyroid patients. In order to reliably detect values of serum TSH in the hyperthyroid range, one needs a third generation assay with a functional sensitivity of at least &le;0.05",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    As an example, second generation methods will often give values well over 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    when the true value is 0.03",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    a typical hyperthyroid value, and can thus lead to a false negative test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/5\">",
"     5",
"    </a>",
"    ]. Third generation values &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    are, however, generally reliable.",
"   </p>",
"   <p>",
"    Presently there is considerable controversy as to the appropriate upper limit of normal for serum TSH. Most laboratories have used values of about 4.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    A monograph published by the National Academy of Clinical Biochemistry argues that the upper limit of normal of the euthyroid reference range should be reduced to 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    because 95 percent of rigorously screened euthyroid volunteers have serum values between 0.4 and 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a population study from Germany, which excluded patients with a positive family history, goiter, nodules, or positive anti-TPO antibodies, found a normal reference range of 0.3 to 3.63",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/7\">",
"     7",
"    </a>",
"    ]. The use of 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    as the upper limit of normal for serum TSH will increase substantially the number of patients in the United States diagnosed with subclinical hypothyroidism. Presently, controversy exists as to whether patients with serum TSH values between 5 and 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    require treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .) Until there are data demonstrating an adverse biologic significance for serum TSH values between 2.5 and 5.0",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    the wisdom of labeling such patients as hypothyroid is questionable.",
"   </p>",
"   <p>",
"    Age-based normal ranges for TSH are important, as illustrated by an analysis of 16,533 individuals in the National Health and Nutrition Examination Survey III (NHANES III) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/8\">",
"     8",
"    </a>",
"    ]. In this report, there was an age-related shift towards higher TSH concentrations in older patients, which persisted when those with positive antithyroid antibodies were excluded. For example, the 97.5 centile for TSH in subjects aged 20 to 29 years or over age 80 was 3.56 and 7.49",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    respectively. Seventy percent of subjects in the older group with a TSH greater than 4.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    were within the normal range for their age. Similar age-associated increases in serum TSH concentrations were found in other prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum T4 and T3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum total T4 is usually measured by radioimmunoassay (RIA), chemiluminometric assay, or similar immunometric technique. Virtually all (99.97 percent) of serum T4 is bound to TBG (thyroxine binding globulin), transthyretin (also called or TBPA [thyroxine-binding prealbumin]), or albumin. Serum total T4 assays measure both bound and unbound (\"free\") T4. Normal ranges vary among laboratories; a typical range is 4.6 to 11.2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (60 to 145",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Serum",
"    T3 is also measured by RIA, chemiluminometric assay or other immunometric assay. T3 is less tightly bound to TBG and TBPA, but more tightly bound to albumin than T4. The normal range is even more variable among laboratories than that for total T4; a typical range is approximately 75 to 195",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (1.1 to 3",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serum free T4 and free T3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The free hormone hypothesis states that the unbound or free hormone is that which is available for uptake into cells and interaction with nuclear receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/12\">",
"     12",
"    </a>",
"    ]. The bound hormone, on the other hand, represents a circulating storage pool that is not immediately available for uptake into cells.",
"   </p>",
"   <p>",
"    Since drugs and illness can alter concentrations of binding proteins or interaction of the binding proteins with T4 or T3 (",
"    <a class=\"graphic graphic_table graphicRef50439 \" href=\"UTD.htm?21/19/21820\">",
"     table 2",
"    </a>",
"    ), the free and total hormone concentrations may not be concordant. An example is estrogen-induced TBG excess in which total T4 concentrations are high due to increased TBG-bound hormone, but the physiologically important free T4 concentrations are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .) It is therefore necessary to estimate free hormone concentrations.",
"   </p>",
"   <p>",
"    Four different tests have been used to estimate the free T4: equilibrium dialysis, \"direct\" free hormone measurements, calculating the free hormone index by using the thyroid hormone-binding ratio or index (THBR or THBI) via measurement of the T3 resin uptake, and calculating the ratio of total thyroid hormone to TBG (thyroxine binding globulin) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/13\">",
"     13",
"    </a>",
"    ]. Because none of these methods measure free T4 directly, guidelines suggest that these methods be named \"free T4 estimate tests\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/6\">",
"     6",
"    </a>",
"    ]. Most laboratories measure free T4 using only two of these four methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Direct\" free T4 &mdash; \"Direct\" free T4 measurements are increasingly popular. Varying methodologies have been used by commercial laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/14\">",
"       14",
"      </a>",
"      ]; however, none of these kits actually measure unbound T4 directly, since free hormone represents only 0.03 percent of serum total T4. The perceived advantage of direct free T4 measurement is that confusion related to binding protein abnormalities is mitigated by providing values that allegedly take binding abnormalities into account. The disadvantage is that no currently available kit provides correct free T4 values for all the binding abnormalities that have been described. Direct free T4 measurements may be unreliable during pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"       \"Overview of thyroid disease in pregnancy\"",
"      </a>",
"      ). The normal range varies with the methodology used.",
"      <br/>",
"      <br/>",
"      Direct T3 measurements are also available, but have limited utility.",
"     </li>",
"     <li>",
"      Free T4 index &mdash; Calculation of the free T4 index has the advantage that the clinician is given both a total T4 and a thyroid hormone binding ratio or index, making it clear when the patient has a potential binding protein abnormality. The disadvantages are: (1) the calculation is poorly understood by many clinicians, and (2) the free T4 index, as with direct free T4 measurements, fails to give correct values for many described binding protein abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"       \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     T3-resin uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T3-resin uptake is the traditional test utilized to calculate the free hormone index. This test is performed by incubating the patient's serum with radiolabeled T3 tracer and subsequently adding an insoluble resin that traps the remaining unbound radiolabeled T3. A typical resin is dextran-coated charcoal. The value reported is the percent tracer bound to the resin, which varies inversely with the number of available free binding sites for T3. The number of free binding sites is determined by both binding protein levels and endogenous hormone production.",
"   </p>",
"   <p>",
"    The normal range varies considerably among laboratories. While many laboratories still report the actual measured value for the T3 resin, it is preferable to calculate a THBR or THBI (thyroid hormone binding ratio or index), which is simply a normalized T3-resin uptake value [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    THBI &nbsp;= &nbsp;patient's T3 resin &nbsp;&divide; &nbsp;normal pool T3 resin",
"   </p>",
"   <p>",
"    The mean THBI is therefore by definition 1.00, with a normal range of approximately 0.83 to 1.16.",
"   </p>",
"   <p>",
"    The free T4 index approximates the free T4 by dialysis and is calculated by \"correcting\" the total T4 by the binding ratio or index:",
"   </p>",
"   <p>",
"    Free T4 index &nbsp;= &nbsp;total T4 &nbsp;x &nbsp;THBI",
"   </p>",
"   <p>",
"    If the index is calculated by using the T3-resin measurement directly, the result is a unitless number with a normal range distinct for the laboratory. If, on the other hand, the index is calculated using the THBI, the index should have approximately the same normal range as the total T4 values for the laboratory.",
"   </p>",
"   <p>",
"    The T3-resin uptake was designed to distinguish TBG excess and deficiency from hyperthyroidism and hypothyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperthyroidism &mdash; high serum total T4, high T3-resin uptake or THBI, high free T4 index",
"     </li>",
"     <li>",
"      TBG excess &mdash; high serum total T4, low T3-resin uptake or THBI, normal free T4 index",
"     </li>",
"     <li>",
"      Hypothyroidism &mdash; low serum total T4, low T3-resin uptake or THBI, low free T4 index",
"     </li>",
"     <li>",
"      TBG deficiency &mdash; low serum total T4, high T3-resin uptake or THBI, normal free T4 index",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the index may not fully correct at the extremes of binding protein abnormalities.",
"   </p>",
"   <p>",
"    A serum free T3 index can also be calculated using the THBI.",
"   </p>",
"   <p>",
"    Measurement of free T4 by equilibrium dialysis is available only in a few reference laboratories. The classic technique measures the distribution of radiolabeled T4 tracer across a dialysis membrane to estimate the unbound fraction. The method is too tedious and expensive for routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF THYROID FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function tests are used in a variety of clinical settings to screen thyroid function, assess the adequacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    therapy, and monitor the treatment of hyperthyroidism (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Screening for thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Screening\" refers to the measurement of thyroid function tests in patients at risk of having thyroid disease who are presently not known to have thyroid disease. There is some debate over the cost-effectiveness of screening or case-finding in apparently asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second and third generation serum TSH assays are both more sensitive and specific than serum free T4 measurements for outpatients if a single screening test is utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, some experts recommend that both serum TSH and free T4 be measured in all patients for screening purposes, since errors may be made when only TSH is measured in patients with secondary or central hypothyroidism or TSH-mediated hyperthyroidism.",
"   </p>",
"   <p>",
"    This approach adds considerable cost to screening, and is likely to pick up few cases of unsuspected pituitary disease. As a result, many laboratories are using strategies such as the following to limit unnecessary laboratory testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum TSH normal &mdash; no further testing performed",
"     </li>",
"     <li>",
"      Serum TSH high &mdash; free T4 added to determine the degree of hypothyroidism",
"     </li>",
"     <li>",
"      Serum TSH low &mdash; free T4 and T3 added to determine the degree of hyperthyroidism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We make two amendments to this strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected (eg, a young woman with amenorrhea and fatigue).",
"     </li>",
"     <li>",
"      We measure serum free T4 if the patient has convincing symptoms of hyper- or hypothyroidism despite a normal TSH result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening inpatients is a more difficult problem and is not recommended unless thyroid disease is strongly suspected since changes in thyroid hormones, binding proteins, and TSH concentrations occur in severe nonthyroidal illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .) These changes may include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low concentrations of all three binding proteins",
"     </li>",
"     <li>",
"      High concentrations of free fatty acids that displace thyroid hormones from binding proteins",
"     </li>",
"     <li>",
"      Acquired central hypothyroidism",
"     </li>",
"     <li>",
"      The patient may be receiving medications that affect thyroid function (",
"      <a class=\"graphic graphic_table graphicRef50439 \" href=\"UTD.htm?21/19/21820\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are advocates for either serum TSH or free T4 being more useful in these patients, most experts suggest both serum TSH and free T4 are necessary to assess thyroid function in them [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring levothyroxine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more common reasons for assessing thyroid function is to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (Synthroid, Levoxyl, Unithyroid, Levothroid, Tirosint, and generics) therapy. Patients with primary hypothyroidism who are taking levothyroxine replacement therapy can be monitored by assessing the serum TSH. If serum TSH is high, the dose needs to be increased; if it is low, the dose needs to be reduced. Excess suppression of serum TSH can increase the risk of both atrial fibrillation and bone disease due to subclinical hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hypothyroidism\", section on 'Dose and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum free T4 measurements are very insensitive for assessing the appropriateness of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    dose. As an example, doses of levothyroxine that are 40 percent higher than optimal result in subnormal serum TSH concentrations, yet free serum T4 concentrations frequently remain within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/22\">",
"     22",
"    </a>",
"    ]. The one setting in which the serum free T4 value should be used to titrate the thyroid hormone dose is in patients with secondary hypothyroidism due to pituitary or hypothalamic disease, who have impaired TSH release. In this situation, the free T4 level should be maintained in the upper 50 percent of the normal range.",
"   </p>",
"   <p>",
"    The goal and requirement for monitoring are different in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    for suppression of TSH secretion to prevent recurrence of thyroid cancer or growth or regrowth of goitrous tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    .) These patients should have undetectable or subnormal serum TSH concentrations, depending on the clinical situation. As a result, it is necessary to measure both serum free T4 and TSH to assess the appropriateness of therapy if one is utilizing a second-generation TSH assay. In this setting, the serum TSH should be subnormal, but the serum free T4 should not be excessively elevated. If, on the other hand, a third generation TSH assay is available, then measurement of serum TSH alone may be sufficient. In thyroid cancer, the goal of therapy is generally accepted to be a serum TSH concentration less than 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    for patients with persistent or metastatic disease. However, in patients with no evidence of disease after a period of observation, reducing the levothyroxine dose so that the serum TSH is only slightly subnormal will minimize the adverse effects of suppressive therapy. Similarly, the goal of therapy in goiter patients is a slightly subnormal serum TSH concentration, eg, greater than 0.06",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    but less than 0.5",
"    <span class=\"nowrap\">",
"     mU/L;",
"    </span>",
"    at this concentration, the serum free T4 concentration is almost always normal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following strategy for monitoring suppressive therapy may be used with a third generation TSH assay:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Third generation serum TSH value normal &mdash; increase",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      dose",
"     </li>",
"     <li>",
"      Third generation serum TSH value 0.06 to 0.5",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      &mdash; appropriate for suppressive therapy; adjust dose if indicated",
"     </li>",
"     <li>",
"      Third generation serum TSH value &lt;0.05",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      &mdash; add serum free T4 to assess the degree of potentially excessive therapy; adjust dose if indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum TSH is only accurate if steady state conditions are present, which takes four to six weeks after starting or adjusting the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    dose. This does not mean that one has to wait four to six weeks before making any adjustment in dose. Knowing that the half-life of thyroxine is about one week, measurement of serum free T4 after two or three half-lives, as an example, might allow one to make gross adjustments in the levothyroxine dose even though the serum TSH has not yet had time to fully equilibrate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/51/1846?source=see_link\">",
"     Liothyronine",
"    </a>",
"    (T3, Cytomel) is generally not recommended for treating hypothyroidism. However, in patients with persistent symptoms on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    , T3 is sometimes added. If the ratio of T4 to T3 administered is below 10:1 (normal ratio approximately 14:1), assessment of therapy requires measurement of serum T3 and TSH, since serum T4 will remain low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring treatment of hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum T3 concentrations are disproportionately higher than serum T4 concentrations in many types of hyperthyroidism. As a result, serum T3 measurements may be valuable for evaluating and following patients with this disorder. Serum TSH measurements are useful for the diagnosis of hyperthyroidism, but they are unable to distinguish the degree of hyperthyroidism since suppression occurs in the early stages of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .) During the early treatment of hyperthyroidism, serum TSH may remain subnormal for several weeks and rarely for several months. One must therefore rely upon serum free T4 and T3 measurements when assessing the efficacy of antithyroid drugs, radioiodine, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. Once steady-state conditions are assured, measurement of serum TSH is required to assess the efficacy of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTITHYROID ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antibodies against thyroid antigens have been described in chronic autoimmune thyroiditis. The antigens include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thyroglobulin (Tg, formerly known as the colloid antigen)",
"     </li>",
"     <li>",
"      Thyroid peroxidase (TPO, formerly known as the microsomal antigen)",
"     </li>",
"     <li>",
"      The TSH receptor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thyroglobulin (Tg) is synthesized by follicular cells and secreted into the lumen of the thyroid follicle, where it is stored as colloid. Thyroid peroxidase (TPO) catalyzes the iodination of tyrosine&nbsp;residues of Tg to form monoiodotyrosine and diiodotyrosine. Nearly all patients with Hashimoto's thyroiditis have high serum concentrations of antibodies to Tg and TPO. TSH receptor antibodies (TRAb) have been classified as stimulating, blocking, or neutral. TSH receptor antibodies of the stimulating variety (thyroid stimulating immunoglobulins) cause Graves&rsquo; disease. However, both TSH receptor blocking and stimulating antibodies are seen in patients with Graves&rsquo; disease. TSH receptor blocking antibodies may also be seen in patients with atrophic Hashimoto&rsquo;s thyroiditis. The role of these antibodies in the pathogenesis of autoimmune thyroid disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine measurement of antithyroid antibodies is not necessary for the assessment of thyroid function. As an example, serum antithyroid peroxidase antibodies need not be measured in patients with overt primary hypothyroidism because almost all have chronic autoimmune thyroiditis. However, a test for antithyroid peroxidase antibodies may be useful to predict the likelihood of progression to permanent overt hypothyroidism in patients with subclinical hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H7#H7\">",
"     \"Subclinical hypothyroidism\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of TSH receptor antibodies (TRAb) is unnecessary for establishing the cause of hyperthyroidism if a radioiodine uptake has been obtained. However, TRAb measurements are being used increasingly as an alternative and may be useful when a radioiodine uptake is unavailable or contraindicated (eg, to distinguish Graves&rsquo; hyperthyroidism from postpartum thyroiditis in a nursing mother). TRAb measurements are also useful for assessing the likelihood of remission after a course of antithyroid drugs in patients with Graves&rsquo; disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnosis of hyperthyroidism\", section on 'Determining the etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link&amp;anchor=H8#H8\">",
"     \"Postpartum thyroiditis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link&amp;anchor=H11#H11\">",
"     \"Thionamides in the treatment of Graves' disease\", section on 'Can remission be predicted?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of assay used to detect TRAb depends upon local availability. Thyroid stimulating immunoglobulin (TSI) assays measure the ability of the antibody to bind to the TSH receptor and stimulate adenylate cyclase production. While they are very specific for Graves&rsquo; disease, they are less sensitive and may be normal in mild hyperthyroidism. The second generation TSH receptor binding inhibitor immunoglobulin (TBII) assays measure stimulating, blocking, and neutral antibodies. They are more sensitive but may be less specific for Graves&rsquo; hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3608/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30113367\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function tests are used in a variety of clinical settings to screen for thyroid dysfunction, assess the adequacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    therapy in patients with hypothyroidism, and monitor the treatment of hyperthyroidism (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30113378\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Screening\" refers to the measurement of thyroid function tests in patients at risk of having thyroid disease who are presently not known to have thyroid disease. Most laboratories use serum TSH as the initial screening test as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum TSH normal &mdash; no further testing performed",
"     </li>",
"     <li>",
"      Serum TSH high &mdash; free T4 added to determine the degree of hypothyroidism",
"     </li>",
"     <li>",
"      Serum TSH low &mdash; free T4 and T3 added to determine the degree of hyperthyroidism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We make two amendments to this strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected (eg, a young woman with amenorrhea and fatigue).",
"     </li>",
"     <li>",
"      We measure serum free T4 if the patient has convincing symptoms of hyper- or hypothyroidism despite a normal TSH result. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Screening for thyroid dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30113385\">",
"    <span class=\"h2\">",
"     Monitoring thyroxine therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary hypothyroidism who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      replacement therapy can be monitored by assessing the serum TSH. If serum TSH is high, the dose needs to be increased; if it is low, the dose needs to be reduced. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring levothyroxine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal and requirement for monitoring are different in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      for suppression of TSH secretion to prevent recurrence of thyroid cancer or growth or regrowth of goitrous tissue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H30#H30\">",
"       \"Overview of the management of differentiated thyroid cancer\", section on 'Levothyroxine suppression'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"       \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30113419\">",
"    <span class=\"h2\">",
"     Monitoring hyperthyroid patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early treatment of hyperthyroidism, serum TSH may remain subnormal for several weeks and rarely for several months. One must therefore rely upon serum free T4 and T3 measurements when assessing the efficacy of antithyroid drugs, radioiodine, or surgery. Once steady-state conditions are assured, measurement of serum TSH is required to assess the efficacy of therapy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Monitoring treatment of hyperthyroidism'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/1\">",
"      Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/2\">",
"      Caldwell G, Kellett HA, Gow SM, et al. A new strategy for thyroid function testing. Lancet 1985; 1:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/3\">",
"      Nicoloff JT, Spencer CA. Clinical review 12: The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab 1990; 71:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/4\">",
"      Ross DS, Ardisson LJ, Meskell MJ. Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. J Clin Endocrinol Metab 1989; 69:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/5\">",
"      Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/6\">",
"      Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/7\">",
"      Kratzsch J, Fiedler GM, Leichtle A, et al. New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 2005; 51:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/8\">",
"      Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/9\">",
"      Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012; 97:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/10\">",
"      Waring AC, Arnold AM, Newman AB, et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab 2012; 97:3944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/11\">",
"      Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and Gender-Specific TSH Reference Intervals in People With No Obvious Thyroid Disease in Tayside, Scotland: The Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab 2013; 98:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/12\">",
"      Ekins R. The free hormone hypothesis and measurement of free hormones. Clin Chem 1992; 38:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/13\">",
"      Midgley JE. Direct and indirect free thyroxine assay methods: theory and practice. Clin Chem 2001; 47:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/14\">",
"      Wong TK, Pekary AE, Hoo GS, et al. Comparison of methods for measuring free thyroxin in nonthyroidal illness. Clin Chem 1992; 38:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/15\">",
"      Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid-related proteins in serum. J Clin Endocrinol Metab 1987; 64:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/16\">",
"      de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 1989; 149:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/17\">",
"      Surks MI, Chopra IJ, Mariash CN, et al. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 1990; 263:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/18\">",
"      DeGroot LJ, Mayor G. Admission screening by thyroid function tests in an acute general care teaching hospital. Am J Med 1992; 93:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/19\">",
"      Ross DS. Screening thyroid function tests in an acute-care hospital. Am J Med 1994; 96:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/20\">",
"      Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/21\">",
"      Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/22\">",
"      Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/23\">",
"      Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990; 71:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/24\">",
"      Ehrmann DA, Sarne DH. Serum thyrotropin and the assessment of thyroid status. Ann Intern Med 1989; 110:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3608/abstract/25\">",
"      Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun Rev 2009; 9:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7891 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3608=[""].join("\n");
var outline_f3_33_3608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30113367\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LABORATORY TESTS USED TO ASSESS THYROID FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serum TSH concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum T4 and T3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serum free T4 and free T3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      T3-resin uptake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL USE OF THYROID FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Screening for thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring levothyroxine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTITHYROID ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30113367\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30113378\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30113385\">",
"      Monitoring thyroxine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30113419\">",
"      Monitoring hyperthyroid patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7891|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10629\" title=\"figure 1\">",
"      Regulation thyroid hormone production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/29/27088\" title=\"figure 2\">",
"      Thyroid hormone synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/20/26956\" title=\"table 1\">",
"      Assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/19/21820\" title=\"table 2\">",
"      Drugs and thyroid function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=related_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3609="Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma";
var content_f3_33_3609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Jennifer R Brown, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3609/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/33/3609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Richter's transformation (RT, Richter's syndrome) was first described in 1928 by Maurice Richter as the development of an aggressive large-cell lymphoma in the setting of underlying chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma",
"    <span class=\"nowrap\">",
"     (CLL/SLL).",
"    </span>",
"    Although diffuse large B cell lymphoma is the most common histology seen in patients with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1\">",
"     1",
"    </a>",
"    ], Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and T cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/4\">",
"     4",
"    </a>",
"    ] have also been reported less commonly. The clinical features, pathogenesis, and treatment of RT will be discussed here.",
"   </p>",
"   <p>",
"    Evolution to a component of B-cell prolymphocytic leukemia (B-PLL) during the natural history of relapsed",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    is also common, but is not usually included under the rubric of RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H23#H23\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Prolymphocytoid transformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of RT from",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    to diffuse large B cell lymphoma has been variously estimated at 2 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1,5-8\">",
"     1,5-8",
"    </a>",
"    ], making it less common than histologic transformation of other low-grade mature B cell malignancies (",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 1",
"    </a>",
"    ). The median time from the diagnosis of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    to transformation has been in the range of two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/5,6,9\">",
"     5,6,9",
"    </a>",
"    ]. For example, a series of 185 consecutive, previously untreated patients with CLL followed for a median of 47 months identified RT in 17 cases (9 percent) at a median of 23 months from diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/8\">",
"     8",
"    </a>",
"    ]. This group took an aggressive approach to repeat biopsy, which may explain the high rate of RT. In addition to those transforming to DLBCL, an additional 0.4 percent of patients will transform to Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of RT is heralded by sudden clinical deterioration, characterized by a marked increase in lymphadenopathy at one or more sites (often abdominal), splenomegaly, and worsening \"B\" symptoms (ie, fever, night sweats, weight loss). The serum level of lactate dehydrogenase (LDH) is elevated in 50 to 80 percent of patients with RT compared with 8 percent of CLL patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/6,9,11\">",
"     6,9,11",
"    </a>",
"    ]. Anemia with a hemoglobin &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is seen in about 50 percent of cases, and thrombocytopenia with a platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    in 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]. Symptoms are similar in the Hodgkin lymphoma variant. The clinical course of RT is rapidly progressive, with a median survival of 5 to 8 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1,6,12-14\">",
"     1,6,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of RT remain poorly defined.",
"   </p>",
"   <p>",
"    In a review of the M D Anderson experience between 1975 and 2005, RT occurred in 148 of 3986 patients with CLL (3.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]. In an earlier report of their experience, clinical features associated with RT included [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated serum lactate dehydrogenase &mdash; 82 percent",
"     </li>",
"     <li>",
"      Progressive lymphadenopathy &mdash; 64 percent",
"     </li>",
"     <li>",
"      Systemic symptoms &mdash; 59 percent",
"     </li>",
"     <li>",
"      Monoclonal gammopathy &mdash; 44 percent",
"     </li>",
"     <li>",
"      Extranodal involvement &mdash; 41 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No clinical, chromosomal, or treatment groups were significantly associated with RT in this study. In a subsequent review of patients seen between 1992 and 2002, the incidence of RT was 5 percent overall, and was as high as 10 to 13 percent in those who had received three or more previous treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other suggested risk factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increasing number of prior therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/6\">",
"       6",
"      </a>",
"      ] and younger age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/15\">",
"       15",
"      </a>",
"      ] have both been associated with higher risk of RT.",
"     </li>",
"     <li>",
"      One analysis found that advanced Rai stage, hemoglobin &lt;12",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and elevated LDH and beta-2-microglobulin levels were associated with increased risk of RT [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective cohort study of 185 patients identified lymph nodes &gt;3cm, absence of del 13q14, CD38 expression and usage of IGHV4-39 as risk factors for RT [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/8\">",
"       8",
"      </a>",
"      ]. Another analysis suggested that CLL with IGHV4-39 and stereotyped B cell receptors had a very high risk of RT (69 percent at five years) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The G allele of a single nucleotide polymorphism (SNP) in the regulatory region of intron 1 of CD38 has been found to increase the upregulation of CD38 in response to IL-2, and this SNP when heterozygous or homozygous has been associated with the development of Richter's syndrome in a modest number of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although immunosuppression related to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has been suggested to promote RT, several studies have found that purine analogue therapy is not a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/6,19,20\">",
"     6,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MAKING THE DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging may be helpful in the initial diagnosis of RT. In one report, 9 of 29 patients suspected of having RT had a positive gallium scan; of those, seven had RT on biopsy and two had fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/21\">",
"     21",
"    </a>",
"    ]. A second study of 37 patients using PET, in which a standardized uptake value (SUV) &gt;5 was considered suggestive of RT, found that 10 of 11 patients with RT were correctly identified by PET, with one patient missed; however, nine additional patients had false positive PET results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'PET scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of a likely site of transformation, usually a site of enlarging lymphadenopathy, is required to establish the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 1",
"    </a>",
"    ). While biopsy remains necessary to establish the diagnosis, imaging, as above, may provide guidance on the choice of biopsy site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant cells of RT can occasionally be seen in the bone marrow and only very rarely in the peripheral blood. An attempt was made to predict the presence of RT without a lymph node biopsy by studying bone marrow in a group of 78 randomly selected patients with CLL and 29 patients with histologically-confirmed RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/23\">",
"     23",
"    </a>",
"    ]. The presence of &gt;7 percent \"large cells\" (greatest nuclear dimension more than twice that of a normal lymphocyte) in the bone marrow along with a serum beta-2 microglobulin level &gt;5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in a patient with CLL predicted for a clinical outcome similar to that of patients with RT (median survival nine months). However, these findings could be explained by advanced progressive CLL even in the absence of RT, and therefore serve more as prognostic markers than as necessary predictors of RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic diagnosis in patients with RT is usually that of a diffuse large B-cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]. In some cases, the CLL and RT cells had a common origin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11,24\">",
"     11,24",
"    </a>",
"    ], while in others the RT cells apparently arose de novo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of Richter&rsquo;s transformation (RT) is likely a complex, multistep process leading to the replication of a malignant clone of germinal or post-germinal B cell origin manifesting as diffuse large B cell lymphoma (DLBCL). There are three possible origins of the aggressive clone:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DLBCL may arise from the underlying",
"      <span class=\"nowrap\">",
"       CLL/SLL",
"      </span>",
"     </li>",
"     <li>",
"      DLBCL may represent evolution from a biclonal phenotype in the",
"      <span class=\"nowrap\">",
"       CLL/SLL",
"      </span>",
"     </li>",
"     <li>",
"      DLBCL may represent a new clone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many cases have been investigated using analysis of immunoglobulin isotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/9\">",
"     9",
"    </a>",
"    ], immunoglobulin heavy chain gene rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1,7,26\">",
"     1,7,26",
"    </a>",
"    ], and chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/27\">",
"     27",
"    </a>",
"    ]. Although DLBCL arising by transformation of other low-grade lymphomas is almost always clonally related, initial reports of Richter&rsquo;s transformation found that DLBCL arises by clear clonal evolution from underlying",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    only about 60 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/28\">",
"     28",
"    </a>",
"    ]. Some of the cases in this initial study were of ambiguous origin, however, and more recent studies have suggested that the DLBCL and CLL more commonly have clonal origins, as much as 90 to 100 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. Significant differences in immunophenotype, for example loss of CD5 or CD23, can occur in the RT regardless of clonal relationship with the underlying CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acquisition of new cytogenetic abnormalities is common in the evolution of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    even without histologic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/29\">",
"     29",
"    </a>",
"    ], but is also associated with RT. A multi-institutional series of 86 patients with RT reported that the most common genetic abnormalities were associated with TP53 disruption (47 percent) or aberrant c-MYC expression (26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/27\">",
"     27",
"    </a>",
"    ]. Disruption of TP53 was more common in DLBCL that was clonally related to CLL (60 versus 23 percent) while c-MYC aberration was equally common in cases clonally related or clonally unrelated to CLL (approximately 30 percent each). Marked aneuploidy has been reported in RT arising from previously untreated CLL with a normal or near-normal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A study using comparative genomic hybridization (CGH) in CLL found on average 1.1 genomic imbalances in early stage CLL, 2.1 in progressive CLL, and 4.7 in RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/29\">",
"     29",
"    </a>",
"    ]. The imbalances previously present in the CLL were maintained in the RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/29\">",
"     29",
"    </a>",
"    ], again suggesting clonal origin.",
"   </p>",
"   <p>",
"    FISH studies of microdissected large cells in the bone marrow of CLL patients with RT have found a higher incidence of loss of 11q (ATM) and 17p (p53), as well as chromosome 20, in the larger DLBCL-like cells than in the adjacent small CLL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/33\">",
"     33",
"    </a>",
"    ]. Deletion of 11q has been reported more commonly in RT than CLL, in one study in all three cases of RT, as compared with 13 of 62 patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    (21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/34\">",
"     34",
"    </a>",
"    ]. Other specific abnormalities associated with RT include acquisition of trisomy 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/35\">",
"     35",
"    </a>",
"    ], and losses of 8p and chromosome 9 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lack of somatic hypermutation of the immunoglobulin heavy chain variable region (IgVH) in CLL is associated with progressive disease and a poor prognosis. Not surprisingly, a few small studies have found that most cases of RT appear to arise from these IgVH unmutated CLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. One study found that 18 of 23 (78 percent) cases of DLBCL RT demonstrated clonality with the underlying CLL by IgVH sequence analysis, and of these, 73 percent of the underlying CLLs had unmutated IgVH genes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/30\">",
"     30",
"    </a>",
"    ]. Interestingly, four of the five RTs that were not clonal with the underlying CLL had mutated IgVH genes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H20#H20\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Defining good and poor prognostic groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible exception to this is the Hodgkin lymphoma variant of RT; Hodgkin lymphoma is usually thought to arise from germinal center or post-germinal center B cells, which are therefore expected to have undergone somatic hypermutation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/38\">",
"     38",
"    </a>",
"    ]. In one study of four cases of Hodgkin variant RT, three lacked expression of ZAP-70, which usually correlates with the presence of somatic hypermutation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/38\">",
"     38",
"    </a>",
"    ]. Five of six cases of CLL associated with Hodgkin variant RT were found to have mutated IgVH genes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some evidence suggests that cases of RT acquire the capacity for somatic hypermutation similar to many cases of DLBCL. RT cases showed higher levels of activation-induced cytidine deaminase (AID) and hypermutation of c-MYC, PAX-5 and RhoH, which were not seen in their predecessor CLLs or CLLs that did not transform [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. Microsatellite instability (MSI) has also been identified in four of nine cases of RT as compared with none of 10 cases of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/40\">",
"     40",
"    </a>",
"    ]. No evidence of mutation of hMLH1 or hMSH2 has been found, but the hMLH1 promoter was found to be hypermethylated in those cases with MSI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of individual tumor-suppressor and cell cycle regulatory genes have also been reported to be associated with RT. P53 mutations are common, detected in three of seven RT tumors as compared with 6 of 40 CLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/41\">",
"     41",
"    </a>",
"    ]. Mutations of",
"    <span class=\"nowrap\">",
"     INK4a/ARF,",
"    </span>",
"    a possible upstream regulator of p53 activity, have been found in 29 percent of RT cases as compared with 4 percent of CLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/42\">",
"     42",
"    </a>",
"    ] and are often present when p53 mutation is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/43\">",
"     43",
"    </a>",
"    ]. Together these mutations are present in about 60 percent of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cell cycle inhibitor p21 has also been found to be overexpressed in 3 of 7 RTs as compared with 3 of 15 CLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/44\">",
"     44",
"    </a>",
"    ]; although most CLLs had strong p27 reactivity and no expression of the retinoblastoma (Rb) protein, the RT tumors had no p27 expression and high expression of Rb [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/44\">",
"     44",
"    </a>",
"    ]. These data suggest that dysregulation of the cell cycle in RT may have a different pattern than that seen in CLL, but whether or not these mutations are truly causative remains unclear.",
"   </p>",
"   <p>",
"    The Epstein-Barr Virus (EBV) has been intermittently implicated in the pathogenesis of RT. The largest pathologic study from the Mayo Clinic found that 4 of 25 (16 percent) patients with DLBCL RT had evidence of EBV in the DLBCL by latent membrane protein (LMP) expression or EBV DNA or RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/45\">",
"     45",
"    </a>",
"    ]. Two other studies found EBV in 5 of 24 cases using similar criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11,46\">",
"     11,46",
"    </a>",
"    ]. Although the pathogenic role of the virus is unclear, evidence for its involvement is probably greatest in the Hodgkin lymphoma variant of RT, in which EBV can be found in the RS cells in a majority of the limited reported cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSTIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, RT has been associated with a dismal prognosis, with median survivals of five to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1\">",
"     1",
"    </a>",
"    ]. In the largest reported series of 148 patients with biopsy-proven RT, of whom 135 received therapy and 130 were assessable, the overall response rate to a variety of regimens was 39 percent, with 12 percent complete responses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]. Although not statistically significant, there appeared to be an improvement in response rate with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , from 34 percent to 47 percent. The median failure-free and overall survivals were seven and eight months, respectively.",
"   </p>",
"   <p>",
"    On multivariate analysis, factors that independently correlated with shorter survival included [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      ECOG (Zubrod) performance status &gt;1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor size &gt;5 cm",
"     </li>",
"     <li>",
"      More than one prior treatment",
"     </li>",
"     <li>",
"      Lactate dehydrogenase level &gt;1.5 times the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Median survivals for those with zero to one, two, three, or four to five of these adverse factors were 1.12, 0.90, 0.33, and 0.14 years, respectively.",
"   </p>",
"   <p>",
"    Another series of 86 patients with biopsy-proven RT reported a median survival from the time of RS diagnosis of 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/27\">",
"     27",
"    </a>",
"    ]. On multivariate analysis, the following factors were independent predictors of shorter survival:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ECOG (Zubrod) performance status &gt;1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Failure to achieve a complete remission after induction therapy for RT",
"     </li>",
"     <li>",
"      TP53 disruption on molecular analysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with an ECOG performance status &gt;1 had a poor outcome, irrespective of the other two factors, with a median survival of 7.8 months. Patients with an ECOG performance status &lt;1 who did not have evidence of TP53 disruption and achieved a complete remission with induction therapy had the best outcomes with a five year survival rate of 70 percent. All other patients had an intermediate prognosis and a median survival of 24.6 months. Of importance, the clonal relationship between the RT and the original CLL was determined in 63 patients, 79 percent of which were clonally related. Patients with clonally unrelated DLBCL had a significantly longer median survival (63 versus 14 months) that resembled that of de novo DLBCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of RT has generally relied on combination chemotherapy such as that used for aggressive non-Hodgkin lymphomas or acute lymphoblastic leukemias, with overall response rates ranging from 5 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/1,47-49\">",
"     1,47-49",
"    </a>",
"    ]. In three reports from M D Anderson, median survival duration was 8 to 10 months despite intensive multiagent chemotherapy (eg, hyper-CVXD, CHOP, ESHAP, MINE, FCR), with or without the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , with complete and overall response rates of 14 and 39 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ], and a rate of early death as high as 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The overall response rate was higher when rituximab was added to the chemotherapy regimen (47 versus 34 percent), although this difference did not attain statistical significance. A combination chemotherapy regimen containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and rituximab (OFAR) has been developed for RT and fludarabine-refractory CLL. Twenty patients with RT were treated, with a 50 percent response rate and a median response duration of 10 months. Unfortunately however the six-month overall survival rate of this group was still only 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/50\">",
"     50",
"    </a>",
"    ]. Whether clonally unrelated DLBCL occurring in the context of CLL proves to have better treatment outcome in prospective studies remains to be determined.",
"   </p>",
"   <p>",
"    Improved therapeutic options are clearly needed. Yttrium-90",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    tiuxetan has been tested in seven patients with no clinical responses and significant hematologic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/49\">",
"     49",
"    </a>",
"    ]. The role of radiation therapy is generally limited to palliation, since RT is rarely a localized disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hodgkin lymphoma variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the Hodgkin lymphoma (HL) variant of RT, data on therapy are limited. The majority of patients have high-risk features if prognostic models for de novo HL are applied [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Disease response and clinical outcomes are worse than in de novo HL but better than in DLBCL RT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. The majority of patients have received combination chemotherapy targeted at HL, including ABVD, MOPP, or CVPP, with a 44 percent response rate in the largest series and some long-term survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/10\">",
"     10",
"    </a>",
"    ]. Aggressive NHL regimens such as those used for DLBCL RT have also been tried, with fewer reported successes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the poor efficacy of combination chemotherapy, short duration of remission, and poor overall survival of patients with RT, autologous and allogeneic hematopoietic stem cell transplantation (HCT) have been explored as a therapeutic options. Data are limited to retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11,51,52\">",
"     11,51,52",
"    </a>",
"    ]. Patients who have chemotherapy sensitive disease appear to benefit from the use of consolidative HCT.",
"   </p>",
"   <p>",
"    A potential benefit from consolidative HCT was demonstrated in a single-center case series of 20 patients with RS treated with chemotherapy or chemoimmunotherapy with or without HCT (3 autologous, 17 allogeneic of which 15 were nonmyeloablative) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"     11",
"    </a>",
"    ]. Estimated three-year overall survival rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      75 percent for patients who underwent allogeneic HCT following an objective response to prior chemotherapy (ie, attainment of CR, CRu, or PR). Four of the 17 patients undergoing allogeneic HCT in this report remained in complete remission, with progression-free survivals between one and six years.",
"     </li>",
"     <li>",
"      27 percent for patients with an objective response to chemotherapy who did not have a consolidative HCT.",
"     </li>",
"     <li>",
"      21 percent for patients with relapsed or refractory RT who underwent allogeneic HCT as salvage therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential benefit from HCT was further supported by a retrospective, multicenter analysis of 59 patients with RS who underwent HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3609/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autologous HCT was performed in 34 patients, 28 of whom had documented chemotherapy sensitive disease. Estimated three-year overall survival and relapse-free survival and the cumulative incidences of relapse and nonrelapse mortality were 59, 45, 43, and 12 percent, respectively.",
"     </li>",
"     <li>",
"      Allogeneic HCT was performed in 25 patients, 16 of whom had documented chemotherapy sensitive disease. Reduced intensity conditioning was used in 18 cases. Estimated three-year overall survival, relapse-free survival, and the cumulative incidences of relapse and nonrelapse mortality were 36, 27, 47, and 26 percent, respectively. When compared with younger adults, those over 60 years at the time of HCT had inferior estimated survival (17 versus 47 percent) and relapse-free survival (0 versus 42 percent) at three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest a benefit from the use of autologous or allogeneic HCT in those patients with chemosensitive disease. A choice among these management options must take into consideration the patient age and comorbidities, as well as the disease status. Autologous HCT may be preferred for older adults",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with chemosensitive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Richter's transformation (RT) should be suspected in patients with chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma",
"    <span class=\"nowrap\">",
"     (CLL/SLL)",
"    </span>",
"    who develop rapidly progressive lymphadenopathy or extranodal sites of disease, systemic symptoms, or elevated levels of serum lactate dehydrogenase. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence and clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is required to confirm the diagnosis, and usually shows a histologic pattern consistent with diffuse large B-cell lymphoma (DLBCL). Occasional patients may have a histologic picture consistent with Hodgkin lymphoma. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Making the diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis and outcome are historically poor for RT and the disease is invariably fatal if left untreated.",
"     </li>",
"     <li>",
"      For patients with the DLBCL histologic pattern of RT, we recommend the use of combination chemotherapy as employed for aggressive lymphoma, combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (eg, CHOP-R) (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"       table 2",
"      </a>",
"      ). (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since complete remissions after chemotherapy are short-lived, and long-term survivors have been reported following hematopoietic stem cell transplantation (HCT), we suggest the use of either nonmyeloablative allogeneic or autologous HCT when first remission has been achieved in patients who are transplant candidates. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Autologous HCT may be preferred in older patients or those with chemotherapy sensitive disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with the Hodgkin lymphoma (HL) variant of RT, data are very limited; we suggest the use of combination chemotherapy regimens employed in patients with advanced stage HL (eg, ABVD) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hodgkin lymphoma variant'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the limited data on treatment outcomes for RT, all patients with RT are best advised to enroll in an appropriately designed clinical trial.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/1\">",
"      Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/2\">",
"      Brecher M, Banks PM. Hodgkin's disease variant of Richter's syndrome. Report of eight cases. Am J Clin Pathol 1990; 93:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/3\">",
"      Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol 2012; 156:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/4\">",
"      Lee A, Skelly ME, Kingma DW, Medeiros LJ. B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter's syndrome. Am J Clin Pathol 1995; 103:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/5\">",
"      Morrison VA, Rai K, Peterson BL, et al. Transformation to Richter's Syndrome or Prolymphocytic Leukemia (PLL): an Intergroup Study (CALGB 9011). Blood 1999; 94:539a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/6\">",
"      Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/7\">",
"      Yee KW, O'Brien SM, Giles FJ. Richter's syndrome: biology and therapy. Cancer J 2005; 11:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/8\">",
"      Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008; 142:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/9\">",
"      Harousseau JL, Flandrin G, Tricot G, et al. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases. Cancer 1981; 48:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/10\">",
"      Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006; 107:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/11\">",
"      Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/12\">",
"      Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer 1978; 41:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/13\">",
"      van Dongen JJ, Hooijkaas H, Michiels JJ, et al. Richter's syndrome with different immunoglobulin light chains and different heavy chain gene rearrangements. Blood 1984; 64:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/14\">",
"      Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002; 43:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/15\">",
"      Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/16\">",
"      Tabuteau S, Fernandez J, Garidi R, et al. Richter's Syndrome in B-CLL: report of 37 cases (abstract). Blood 1999; 94:306b.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/17\">",
"      Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009; 15:4415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/18\">",
"      Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 2008; 111:5646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/19\">",
"      Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004; 40:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/20\">",
"      Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/21\">",
"      Partyka S, O'Brien S, Podoloff D, et al. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation. Leuk Lymphoma 1999; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/22\">",
"      Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006; 47:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/23\">",
"      Ma Y, Mansour A, Bekele BN, et al. The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. Cancer 2004; 100:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/24\">",
"      Cherepakhin V, Baird SM, Meisenholder GW, Kipps TJ. Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. Blood 1993; 82:3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/25\">",
"      Matolcsy A, Casali P, Knowles DM. Different clonal origin of B-cell populations of chronic lymphocytic leukemia and large-cell lymphoma in Richter's syndrome. Ann N Y Acad Sci 1995; 764:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/26\">",
"      Bertoli LF, Kubagawa H, Borzillo GV, et al. Analysis with antiidiotype antibody of a patient with chronic lymphocytic leukemia and a large cell lymphoma (Richter's syndrome). Blood 1987; 70:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/27\">",
"      Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011; 117:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/28\">",
"      Foon KA, Thiruvengadam R, Saven A, et al. Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. Ann Intern Med 1993; 119:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/29\">",
"      Be&agrave; S, L&oacute;pez-Guillermo A, Ribas M, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol 2002; 161:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/30\">",
"      Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007; 31:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/31\">",
"      Fitzgerald PH, McEwan CM, Hamer JW, Beard ME. Richter's syndrome with identification of marker chromosomes. Cancer 1980; 46:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/32\">",
"      Chena C, Cerretini R, Noriega MF, et al. Cytogenetic, FISH, and molecular studies in a case of B-cell chronic lymphocytic leukemia with karyotypic evolution. Eur J Haematol 2002; 69:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/33\">",
"      Lee JN, Giles F, Huh YO, et al. Molecular differences between small and large cells in patients with chronic lymphocytic leukemia. Eur J Haematol 2003; 71:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/34\">",
"      Zhu Y, Monni O, Franssila K, et al. Deletions at 11q23 in different lymphoma subtypes. Haematologica 2000; 85:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/35\">",
"      Brynes RK, McCourty A, Sun NC, Koo CH. Trisomy 12 in Richter's transformation of chronic lymphocytic leukemia. Am J Clin Pathol 1995; 104:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/36\">",
"      Tim&aacute;r B, F&uuml;l&ouml;p Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia 2004; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/37\">",
"      Smit LA, van Maldegem F, Langerak AW, et al. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. Haematologica 2006; 91:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/38\">",
"      Tzankov A, Fong D. Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. Med Hypotheses 2006; 66:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/39\">",
"      Reiniger L, B&ouml;d&ouml;r C, Bogn&aacute;r A, et al. Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia 2006; 20:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/40\">",
"      F&uuml;l&ouml;p Z, Csernus B, T&iacute;m&aacute;r B, et al. Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2003; 17:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/41\">",
"      Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/42\">",
"      Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/43\">",
"      Pinyol M, Hern&aacute;ndez L, Mart&iacute;nez A, et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000; 156:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/44\">",
"      Cobo F, Mart&iacute;nez A, Pinyol M, et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2002; 16:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/45\">",
"      Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol 1999; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/46\">",
"      Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005; 29:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/47\">",
"      Dabaja BS, O'Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001; 42:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/48\">",
"      Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003; 97:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/49\">",
"      Tsimberidou AM, Murray JL, O'Brien S, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004; 100:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/50\">",
"      Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/51\">",
"      Rodriguez J, Keating MJ, O'Brien S, et al. Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 2000; 110:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3609/abstract/52\">",
"      Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012; 30:2211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4728 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3609=[""].join("\n");
var outline_f3_33_3609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MAKING THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT AND PROGNOSTIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hodgkin lymphoma variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4728|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12135\" title=\"picture 1\">",
"      Richters transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 2\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3610="Treatment of male infertility";
var content_f3_33_3610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of male infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Christina Wang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Ronald S Swerdloff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/33/3610/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/33/3610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility in a couple is defined as the inability to achieve conception despite one year of frequent unprotected intercourse. Use of this time period, while arbitrary, was based upon a study of 5574 English and American women engaging in unprotected coitus who ultimately conceived between 1946 and 1956 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/1\">",
"     1",
"    </a>",
"    ]. Among these women, 50 percent conceived within three months, 72 percent within six months, and 85 percent within 12 months. Similar estimates were reported in later studies (",
"    <a class=\"graphic graphic_figure graphicRef80057 \" href=\"UTD.htm?11/24/11661\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are four main causes of male infertility (",
"    <a class=\"graphic graphic_table graphicRef54356 \" href=\"UTD.htm?11/23/11645\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Hypothalamic/pituitary",
"      </span>",
"      disease (secondary hypogonadism) &ndash; 1 to 2 percent",
"     </li>",
"     <li>",
"      Testicular disease (primary spermatogenesis failure and hypogonadism) &ndash; 30 to 40 percent",
"     </li>",
"     <li>",
"      Posttesticular defects (disorders of sperm transport) &ndash; 10 to 20 percent",
"     </li>",
"     <li>",
"      Nonclassifiable &ndash; 40 to 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The noted frequencies represent an estimate of the approximate proportion of patients in each category presenting to a tertiary referral center with capabilities to diagnose subtle defects including Y chromosome microdeletions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/2\">",
"     2",
"    </a>",
"    ]. It is likely that some of the non-classifiable causes will be genetic or epigenetic defects that have not yet been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"     \"Causes of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the treatment of the different causes of male infertility. The current methods of therapy are divided arbitrarily into the following categories: no available treatment, specific treatment, treatment of uncertain efficacy, empirical treatment, and treatment by assisted reproductive techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The diagnostic approach to the infertile male is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of male infertility should be guided by the following general considerations, as well as by the specific causes of the infertility:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Concurrent male and female infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of male infertility involves the couple. The distribution of male and female causes among infertile couples has not been well defined. In a 1982 to 1985 World Health Organization multicenter study, 20 percent of cases were attributed to male factors, 38 percent to female factors, 27 percent had causal factors identified in both partners, and 15 percent could not be satisfactorily attributed to either partner [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is therefore essential that the female partner be thoroughly investigated and treated while the male partner is being evaluated. Problems in the female partner, such as anovulation or irregular ovulation, hyperprolactinemia, endometriosis, and tubal obstruction, should be treated with medications or laparoscopic surgery simultaneously with or before treatment of the male partner. Treatment of the female partner can often compensate for male factor subfertility due to mild to moderate decreases in semen parameters, resulting in pregnancy without treatment of the male. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Use of assisted reproductive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until lately, management of male factor infertility was a frustrating experience for both clinician and patient because of poor understanding of the pathogenesis of and an inability to treat most cases of male infertility. The development of assisted reproductive techniques (ART) has improved the outlook for many couples with male factor infertility. These techniques, however, are complex, invasive, expensive, and often unsuccessful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Documentation of treatment efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medical and surgical procedures have been reported to improve male fertility only to be shown subsequently to be ineffective. The two principal reasons for the initially promising but ultimately misleading reports are the use of semen quality, rather than pregnancy, as the criterion of success, and the failure to include a control group in the trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy should be the principal criterion for efficacy in male fertility studies because semen quality is notoriously variable. When the inclusion criteria require certain abnormal semen test results for entry into a study, subjects may be recruited when their semen parameters are at their worst. These parameters tend to improve subsequently because they regress towards the mean; the improvement gives the false impression of resulting from the study treatment. Use of at least three semen specimens over a period of time, eg, six weeks, may diminish this phenomenon, but is still not as good as pregnancy as the principal criterion of fertility.",
"     </li>",
"     <li>",
"      Male fertility studies should include a control group because even untreated men who have subnormal semen parameters, unless they are entirely azoospermic, can sometimes impregnate their female partners. As a consequence, pregnancy can occur independent of treatment and false positive results occur in clinical studies that do not use a placebo control group [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LIMITED AVAILABLE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of causes of irreversible infertility for which no therapy is available (",
"    <a class=\"graphic graphic_table graphicRef82596 \" href=\"UTD.htm?36/55/37755\">",
"     table 2",
"    </a>",
"    ). As an example, there is no known therapy that will stimulate sperm production when the seminiferous tubules have been severely damaged. Conditions that are often associated with such severe damage are Klinefelter syndrome, microdeletions of the Y-chromosome, Sertoli cell only syndrome, and idiopathic infertility associated with azoospermia.",
"   </p>",
"   <p>",
"    An exception to this generalization is men with azoospermia previously thought to be untreatable as determined by persistent absence of any sperm in the ejaculate but who do have sperm that can be extracted from the seminiferous tubules of the testes. If mature spermatozoa or spermatids are found in the testicular biopsy, they can be retrieved and used to fertilize oocytes in vitro, resulting in pregnancies in the partner using ART (see below).",
"   </p>",
"   <p>",
"    In some cases, successful fertility has been achieved in patients with Klinefelter syndrome and Sertoli cell only syndrome using testicular sperm retrieval and intracytoplasmic sperm injection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/7\">",
"     7",
"    </a>",
"    ]. However, there are important genetic implications of these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link&amp;anchor=H27#H27\">",
"     \"Intracytoplasmic sperm injection\", section on 'Chromosomal abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have germ cell arrest, usually at the primary spermatocyte stage. Microinjections of such early germ cells into the cytoplasm of an oocyte have not resulted in viable embryos for transfer in humans. Microinjection of secondary spermatocytes and round spermatid has resulted in viable embryos in mice but not in men [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been shown that injection of a sperm nucleus can result in viable offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if a man's infertility cannot be treated, the frequently accompanying hypogonadism can be treated with testosterone. While not enhancing fertility potential, such men will greatly benefit from androgen replacement by improvement in sexual function and mood, and an increase in or maintenance of bone and muscle mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPECIFIC TREATMENT AVAILABLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific endocrine treatment is available only for men whose infertility results from hypogonadotropic hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypogonadotropic hypogonadism due to hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hypogonadotropic hypogonadism results from hyperprolactinemia, the hypogonadism can often be corrected and fertility restored by lowering the serum prolactin concentration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the hyperprolactinemia results from a medication, that medication should be discontinued, if possible.",
"     </li>",
"     <li>",
"      If the hyperprolactinemia results from a lactotroph adenoma, the adenoma should be treated with a dopamine agonist, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"       \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal spermatogenesis takes three months. As a result, restoration of a normal sperm count usually does not occur for at least three and sometimes six months or more after the serum prolactin and testosterone concentrations have returned to normal.",
"   </p>",
"   <p>",
"    In some patients who have a lactotroph macroadenoma, the hypogonadotropic hypogonadism appears to be the result of permanent damage to the gonadotroph cells by the mass effect of the adenoma. Lowering the serum prolactin concentration and shrinking the adenoma in this setting may not be sufficient to increase the testosterone concentration and sperm count. Thus, if the serum testosterone concentration does not increase to normal within six months of the serum prolactin being reduced to normal, gonadotropin treatment should be instituted if fertility is desired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypogonadotropic hypogonadism due to other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who have hypogonadotropic hypogonadism due to hypothalamic or pituitary diseases can be treated with gonadotropins, but only men who have hypogonadotropic hypogonadism due to hypothalamic disease can be treated with gonadotropin-releasing hormone (GnRH). A complete discussion of the use of gonadotropins can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadotropin therapy &mdash; Treatment is initiated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"       human chorionic gonadotropin",
"      </a>",
"      (hCG), 1500 to 2000 IU three times per week subcutaneously or intramuscularly for at least six months. hCG has the biologic activity of luteinizing hormone. The hCG dose should be adjusted upward according to symptoms of hypogonadism, serum testosterone concentrations, and semen parameters.",
"      <br/>",
"      <br/>",
"      Some patients with acquired hypogonadotropic states can be stimulated with hCG alone to produce sufficient sperm. If after six to nine months the patient remains azoospermic or severely oligospermic, then human menopausal gonadotropin (hMG) or recombinant FSH should be added. This topic is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link&amp;anchor=H2#H2\">",
"       \"Induction of fertility in men with secondary hypogonadism\", section on 'Gonadotropin therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulsatile&nbsp;GnRH treatment &mdash; Pulsatile subcutaneous or intravenous treatment with gonadotropin releasing hormone (GnRH) has also been successfully used to treat gonadotropin deficient patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/11\">",
"       11",
"      </a>",
"      ]. GnRH has to be delivered in pulses using a portable pump with an attached catheter and needle for many months or years; most patients find it inconvenient to use GnRH therapy for so long. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link&amp;anchor=H7#H7\">",
"       \"Induction of fertility in men with secondary hypogonadism\", section on 'Pulsatile GnRH'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF UNCERTAIN EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for the following conditions have a certain rationale, but the evidence for the efficacy of these treatments may not be conclusive (",
"    <a class=\"graphic graphic_table graphicRef58859 \" href=\"UTD.htm?19/34/20011\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genital infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertile men rarely present with symptoms or signs of acute genital infections or prostatitis, but they are sometimes diagnosed as having infections of the urogenital tract by the presence of increased leukocytes in the semen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/12\">",
"     12",
"    </a>",
"    ]. These patients are often labeled as having chronic prostatitis, but specific organisms are rarely identified. The effect of chlamydia infections on semen quality and infertility remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In such situations, it is unclear if the leukospermia plays a pathogenic role in the infertility or is a correlative event. A pathogenic role seems possible because the presence of leukocytes may decrease sperm functional capacity by the release of reactive oxygen species. Seminal fluid cultures should be obtained when there are over one million leukocytes in the semen; however, the yield is usually poor and nondiagnostic.",
"   </p>",
"   <p>",
"    Despite the absence of symptoms, we typically treat patients who have leukospermia, even if the culture is negative, with at least a 10 day course of antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or a quinolone. A second course of therapy is usually given if leukocytes persist in the semen after antibiotics. However, the poor results of this regimen make it difficult to demonstrate a causal relationship between genital infections and male infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/14\">",
"     14",
"    </a>",
"    ]. Exceptions are patients with a past history of genital gonorrhea, tuberculosis, and other specific sexually transmitted diseases which lead to genital tract obstruction at the epididymis and vas deferens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sperm autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm autoimmunity is diagnosed by the presence of sperm antibodies on the sperm surface or in the seminal fluid by the immunobead test or mixed antiglobulin reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .) Glucocorticoids have been used in such patients. Continuous or intermittent high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (from 40 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for up to six months have been shown in placebo-controlled trials to improve cumulative pregnancy significantly in partners of men with sperm autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, many patients cannot tolerate this regimen because of the adverse effects of high-dose corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) As a result, most couples prefer to try an assisted reproductive technique, such as intracytoplasmic sperm injection (ICSI), as primary treatment for sperm autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Retrograde ejaculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrograde ejaculation, as seen in neuropathic disorders, including urogenital tract surgery, sympathetic denervation, and diabetes, can be treated with intrauterine insemination (IUI), using the male partner's spermatozoa collected after alkalinization of the urine and extensive washing of the sperm. Alternatively, the washed spermatozoa can be used for in vitro fertilization or ICSI procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Varicocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of varicocele can be associated with normal semen parameters and normal fertility, most men with varicocele and presumptive infertility have abnormal semen parameters, including low sperm concentration and abnormal sperm morphology. However, data on the efficacy of varicocele repair for improved fertility are conflicting, and we do not recommend routine varicocele repair in subfertile couples.",
"   </p>",
"   <p>",
"    In a World Health Organization (WHO) study of over 9000 men who were partners in an infertile couple, a varicocele was much more common in men with abnormal semen (25.4 versus 11.7 percent with normal semen) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/17\">",
"     17",
"    </a>",
"    ]. The causal relationship between varicocele and male infertility has been ascribed to increased testicular temperature, delayed removal of endogenously derived toxic materials and metabolites, hypoxia, and stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many years, it has been controversial whether high ligation of varicocele will improve pregnancy rates in the female partner. The World Health Organization (WHO) conducted a large prospective multicenter clinical trial to compare immediate varicocele ligation with operation deferred for one year; 248 couples participated from 12 countries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/20\">",
"     20",
"    </a>",
"    ]. The first year cumulative pregnancy rates were 34.8 percent in the immediate operation group and 16.7 percent in the delayed operation group (p&lt;0.003). In addition to the markedly higher pregnancy rate, sperm concentration was significantly improved at three, six, nine and 12 months after surgery (all p&lt;0.001).",
"   </p>",
"   <p>",
"    These findings suggest that varicocele ligation is approximately 2.5 times more effective than delayed operation. However, there were some flaws in the study design:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was considerable loss of follow-up, particularly in the group of men randomized to delayed operation.",
"     </li>",
"     <li>",
"      At the beginning of the study, some couples were randomized before formal enrollment in the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] and two systematic meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] have reported no definitive benefit of varicocele repair. The WHO study was not included in one of the systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/23\">",
"     23",
"    </a>",
"    ], because the results of the trial were never published in full (only in abstract or summary form with different total numbers of subjects and slightly different benefit estimates).",
"   </p>",
"   <p>",
"    Given this controversy, we do not recommend routine varicocele repair in subfertile couples, although it may be reasonable for men with a large varicocele (grade 3 varicoceles) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition, the response to ligation may be better when the couples are relatively young and the duration of infertility is short. Atrophic testes, elevated serum FSH concentrations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe oligospermia or azoospermia indicate severe general epithelial damage and are associated with a lesser likelihood of fertility after varicocele ligation.",
"   </p>",
"   <p>",
"    In some centers, internal spermatic vein ligation has been replaced with laparoscopic varicocelectomy or vascular catheter embolization of spermatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/27\">",
"     27",
"    </a>",
"    ]. These procedures should only be performed in centers where the surgeon or radiologist is skilled at this procedure.",
"   </p>",
"   <p>",
"    An alternative to varicocele ligation or embolization is an assisted reproductive technique. An analysis comparing ICSI to conventional varicocele ligation showed that surgical varicocelectomy may be more cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/28\">",
"     28",
"    </a>",
"    ]. This conclusion was confirmed in a later study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Obstructive azoospermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive azoospermia can be the result of several processes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"     \"Causes of male infertility\"",
"    </a>",
"    .) It is diagnosed by finding testes of normal size, normal serum FSH concentration, azoospermia or severe oligospermia, and normal testicular histology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both surgery and assisted reproduction techniques may be beneficial in such patients. As an example, obstruction of the epididymis or ejaculatory duct can be treated surgically. Azoospermia due to obstruction in the epididymis can be treated by microsurgical end-to-end anastomosis of the epididymal duct to epididymal duct or to vas. These procedures may lead to the presence of ejaculated sperm, but the results are variable and depend on site of reanastomosis, the experience and skill of the operator, and the duration of obstruction.",
"   </p>",
"   <p>",
"    The results are best when obstructive azoospermia is due to vasectomy and not as good with other causes (eg, postinfection and congenital bilateral absence of the vas deferens) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/30\">",
"     30",
"    </a>",
"    ]. The appearance of spermatozoa after reanastomosis for vasectomy reversal can be over 90 percent, with pregnancy in over 50 percent. The success rate depends upon the duration between vasectomy and the reversal procedure; in general, the longer after vasectomy, the poorer the pregnancy rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ejaculatory duct obstruction is characterized by decreased semen volume and azoospermia or severe oligospermia. Transrectal ultrasonography demonstrates dilated seminal vesicles, and aspiration of the seminal vesicles shows spermatozoa, suggesting obstruction. This condition can be treated by transurethral resection of the ejaculatory ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], with resulting improved semen quality and pregnancy in the partner.",
"   </p>",
"   <p>",
"    In addition, several assisted reproductive techniques can be combined to use sperm from men who have obstructive azoospermia to fertilize ova of their partners and achieve pregnancy. Spermatozoa obtained by microsurgical aspiration from the epididymis (MESA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/34\">",
"     34",
"    </a>",
"    ] or from the testes by biopsy or fine needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/35-37\">",
"     35-37",
"    </a>",
"    ] can be used with eggs aspirated from the female partner for in vitro fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/34\">",
"     34",
"    </a>",
"    ] or ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The fertilization rate of microsurgical sperm aspiration together with ICSI, despite very poor",
"    <span class=\"nowrap\">",
"     epididymal/testicular",
"    </span>",
"    sperm quality, is approximately 50 percent, and the pregnancy rate is about 40 percent per cycle and 20 percent per microsurgical aspiration. Thus, men previously classified as sterile can now be fertile.",
"   </p>",
"   <p>",
"    For obstruction due to vasectomy, surgical reanastomosis appears to be preferable to assisted reproductive techniques. In two separate studies for patients seeking pregnancy after vasectomy, vasectomy reversal was found to be more successful and cost-effective than microsurgical epididymal sperm aspiration followed by IVF or ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one analysis based upon expected costs and results in the United States in 1994, the cost of vasectomy reversal was $25,475 with a delivery rate of 47 percent; the respective values for ICSI were $72,521 and 33 percent. In contrast, for obstruction due to other epididymal lesions, the results of surgical anastomosis are not as good as those with sperm retrieval and ICSI. Given the continuous improvements in sperm retrieval and ICSI techniques, surgical reversal versus ART should be discussed with the couple before an informed decision can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because patients who have congenital bilateral absence of the vas deferens may have genetic mutations commonly present in cystic fibrosis, the possibility that they may now have progeny using assisted reproductive techniques means that their offspring might have cystic fibrosis. Thus, such men and their partners who are considering these techniques to achieve pregnancy should have genetic screening and counseling. Screening the female partner may be more cost effective than screening the patient because if she is negative, the risk that their progeny will have cystic fibrosis or congenital bilateral absence of the vas deferens is less than 1 in 1500 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EMPIRICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many treatments have been used empirically for male infertility, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate and other hormones, vitamins, and kallikrein (",
"    <a class=\"graphic graphic_table graphicRef66605 \" href=\"UTD.htm?1/30/1516\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/3,43,44\">",
"     3,43,44",
"    </a>",
"    ]. However, when placebo-controlled prospective clinical trials have been performed with adequate numbers of subjects in randomized placebo controlled trials, none of these methods, including clomiphene citrate and human recombinant FSH, has been proven clinically effective in idiopathic oligospermia or azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of four randomized controlled trials reported that gonadotropin administration may result in a higher pregnancy rate per couple. However, none of the studies had an adequate sample size. The authors stated that the number of trials and participants was insufficient to draw final conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that aromatase inhibitors may improve sperm concentrations in men with severe oligozoospermia or azoospermia prior to sperm retrieval for ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In one uncontrolled study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    administration to infertile men with serum low testosterone-to-estradiol ratios resulted in an increased testosterone-to-estradiol ratio and an increase in sperm concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/52\">",
"     52",
"    </a>",
"    ]. Further data are necessary before recommending this approach.",
"   </p>",
"   <p>",
"    Another recommendation that has often been made to infertile men is to wear boxer undershorts instead of jockey style and not to take hot showers or baths. The rationale is that increased scrotal temperature can impair spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/53\">",
"     53",
"    </a>",
"    ]; moderate increases in scrotal temperature have been shown to markedly accelerate germ cell apoptosis in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/54\">",
"     54",
"    </a>",
"    ]. However, a study of men who wore tight athletic supporters lined with polyester for 12 months found a slight rise in scrotal temperature but no impairment in semen quality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/55\">",
"     55",
"    </a>",
"    ]. The wearing of ordinary brief underwear had no effect on scrotal temperature compared to boxer-style underwear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/56\">",
"     56",
"    </a>",
"    ]. Similarly, no change in semen parameters was found in men taking frequent saunas or hot baths [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/57\">",
"     57",
"    </a>",
"    ]. Presumably, the degree of intratesticular temperature increase was insufficient to induce the apoptosis seen in experimental animals. We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend use of the treatments listed in the table in the treatment of idiopathic male infertility (",
"    <a class=\"graphic graphic_table graphicRef66605 \" href=\"UTD.htm?1/30/1516\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ASSISTED REPRODUCTIVE TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assisted reproductive techniques are commonly used for the treatment of the female partner of men with moderate or severe oligospermia and azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intrauterine insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrauterine insemination (IUI) procedure consists of washing an ejaculated semen specimen to remove prostaglandins, concentrating the sperm in a small volume of culture media, and injecting the sperm suspension directly into the upper uterine cavity using a small catheter threaded through the cervix. The insemination is timed to take place just prior to ovulation, typically using home urine luteinizing hormone (LH) measurement. A systematic review reported that there is insufficient evidence to recommend one sperm preparation technique over another [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In early studies of couples with male infertility, IUI did not appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, other data suggest that in couples with mild male infertility, IUI does improve pregnancy rates in couples when compared to intracervical insemination or timed natural cycles. The topic of IUI alone or in conjunction with gonadotropin stimulation of the female partner is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link&amp;anchor=H9#H9\">",
"     \"Unexplained infertility\", section on 'Intrauterine insemination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;When in vitro fertilization (IVF) is employed using the ejaculated sperm from a man with moderate oligospermia, the pregnancy rates are very low. Before the advent of intracytoplasmic sperm injection (ICSI), IVF was used for the treatment of male infertility in patients with moderate oligospermia. However, when the sperm concentration was below five",
"    <span class=\"nowrap\">",
"     million/mL",
"    </span>",
"    and sperm motility was poor, the fertilization rate of the oocytes was much less than when the sperm count was normal. The result was an unacceptably low pregnancy and take-home baby rate (less than 10 percent).",
"   </p>",
"   <p>",
"    Other micromanipulation techniques, such as partial zona dissection and subzonal insertion of spermatozoa from severely oligospermic men, are also associated with low fertilization rate or polyspermic fertilization. They do not significantly improve the chance of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intracytoplasmic sperm injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracytoplasmic sperm injection (ICSI) has revolutionized the treatment and improved the prognosis for fertility of men with very severe oligospermia, asthenospermia (low sperm motility), teratospermia (a higher rate of abnormal sperm morphology), and even azoospermia. This technique involves the direct injection of a single spermatozoon into the cytoplasm of a human oocyte, usually obtained from follicles produced under controlled ovarian hyperstimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of ICSI using spermatozoa from infertile men who had severe oligospermia or who had failed IVF was documented in a series of studies from Belgium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. This technique has also been successful in men with nonmosaic Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/66-68\">",
"     66-68",
"    </a>",
"    ], where spermatozoa are obtained from testicular biopsies.",
"   </p>",
"   <p>",
"    ICSI has been adopted by most IVF centers throughout the world. The overall fertilization rate is about 60 percent and the clinical pregnancy rate per cycle is about 20 percent while the multiple pregnancy rate is about 29 to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/58,69,70\">",
"     58,69,70",
"    </a>",
"    ]. The ICSI results are not influenced by either the cause of the azoospermia or the origin of the spermatozoa. This rate is similar to that of IVF in patients with tubal infertility and compares favorably with the 30 percent per cycle chance of successful pregnancy in a couple following natural intercourse. One long-term study reported that the cumulative pregnancy and cumulative live birth rates are comparable between ICSI-IVF and natural pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/71\">",
"     71",
"    </a>",
"    ]. As a result, we recommend that a couple whose infertility is mostly due to a male factor should seek ART treatment only in a center in which ICSI is available.",
"   </p>",
"   <p>",
"    When there are no sperm in the ejaculate but there are germ cells in the testes, ICSI can be performed with spermatozoa isolated from testicular biopsies or fine needle aspirates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Success is dependent on retrieving adequate numbers of spermatozoa or spermatids from the biopsies. Successful pregnancy has been reported even with injection of fresh or cryopreserved immature sperm cells, such as elongated and round spermatids, but not with spermatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The ability of testicular spermatozoa to fertilize human oocytes has been reported in azoospermic men with maturation arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/76\">",
"     76",
"    </a>",
"    ], defective spermiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/77\">",
"     77",
"    </a>",
"    ], deletion of the DAZ gene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/78\">",
"     78",
"    </a>",
"    ], Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/79\">",
"     79",
"    </a>",
"    ], and in men with long-standing azoospermia after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of spermatozoa from men with severe sperm abnormality and genetic disorders to fertilize human oocytes raises the concern over the frequency of chromosomal abnormalities and congenital malformations in live births following ICSI. These data are discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link&amp;anchor=H19#H19\">",
"     \"Intracytoplasmic sperm injection\", section on 'Pregnancy and Pediatric Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    ) but are summarized here [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cumulative study in Belgium, prenatal karyotypes in 1082 pregnancies demonstrated de novo autosomal or sex chromosome abnormalities in 1.7 percent, and inherited structural abnormalities in 0.9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/84\">",
"       84",
"      </a>",
"      ]. The major congenital malformation rate was 2.6 percent in ICSI-induced pregnancies, within the range of that seen in natural pregnancies. Similar results (2.6 percent congenital malformation rate) were noted in a series of 578 infants born after ICSI in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/85\">",
"       85",
"      </a>",
"      ]. Normal neurodevelopmental scores were seen in 208 infants in the United Kingdom compared with control infants [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of serious congenital malformations in 1139 children born after ICSI in Sweden was higher at 4.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/87\">",
"       87",
"      </a>",
"      ]. However, the increase was mainly due to an increased multiple gestation rate. The only specific malformation that occurred in excess after ICSI was hypospadias (RR 3.0), possibly due to paternal infertility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are other reports that suggest that a more significant problem is associated with ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from Australia, the odds ratio was 2.0 for major birth defects for children born from ICSI and IVF compared with natural conception [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from 42,463 infants born after ART procedures from 1996 to 1997 in the United States compared with 3.3 million born from natural conception in 1997 showed a disproportionate number of low birth weight and very low birth weight infants. Singleton births after ART were associated with a 2.7-fold increased risk of low birth weight compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single pregnancies from ART are associated with poorer perinatal outcomes, but not twin pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Couples selecting ICSI as the method of treatment should be counseled about the results of these studies in addition to the risk of transmitting sex-chromosome aberrations and fertility problems to their offspring. In men with Klinefelter syndrome and those with Y microdeletions, including those with deletions of the gene, their offspring might carry the same gene or have an increased risk of sex chromosome aneuploidy, and the infertility might not be detected unless special genetic studies are performed.",
"   </p>",
"   <p>",
"    In a review of 20 Klinefelter patients undergoing ART (with a total of 113 embryos), preimplantation genetic diagnosis (PGD) showed a significantly lower number of normal embryos when compared with a control group with X-linked disease undergoing PGD to determine sex (54 versus 77 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, sex chromosome and autosome abnormalities were more common in embryos from the Klinefelter group. Thus, a cautious approach and counseling should be used in patients with non-mosaic Klinefelter syndrome, and preimplantation genetic diagnosis should be considered.",
"   </p>",
"   <p>",
"    In couples with non-male-factor infertility, IVF with ICSI offers no clinical advantage when compared with conventional IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/91\">",
"     91",
"    </a>",
"    ]. Thus, ICSI should be reserved for those with moderate to severe male-factor infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Retrieval of sperm from the testis",
"    </span>",
"    &nbsp;&mdash;&nbsp;New surgical techniques have been introduced to retrieve spermatozoa from patients with nonobstructive azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/92\">",
"     92",
"    </a>",
"    ]. A technique called microdissection of the testis to extract sperm (TESE) from the seminiferous tubules has been successful in obtaining sperm in over 50 percent of patients with nonobstructive azoospermia, including patients with Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/7,93\">",
"     7,93",
"    </a>",
"    ]. Sperm retrieval rates are higher in Klinefelter syndrome patients with serum testosterone near the reference range (&gt;250",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/51\">",
"     51",
"    </a>",
"    ]. TESE should only be performed in a center where the urologist has been trained and is skillful in these procedures.",
"   </p>",
"   <p>",
"    This technique is also used in men who become azoospermic post-chemotherapy. Ideally, men who will be undergoing chemotherapy should be referred for sperm banking. However, only 50 percent are offered this option and even fewer result in cryopreserved sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/94\">",
"     94",
"    </a>",
"    ], in spite of current guidelines from the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/95\">",
"     95",
"    </a>",
"    ]. In the past, men who developed azoospermia after chemotherapy were considered to be sterile. Now, many of these men (approximately 37 percent in one study) are able to undergo successful testicular sperm extraction and intracytoplasmic sperm injection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Artificial insemination with donor semen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alternative to ART for many couples, including those who fail ART, is artificial insemination with donor sperm. This time-tested method has a very high success rate in apparently normal female recipients: 50 percent pregnancy rate with six cycles of insemination. Children born from pregnancies resulting from donor insemination grow and develop normally, both physically and psychologically [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/97\">",
"     97",
"    </a>",
"    ]. This alternative, together with adoption and childlessness, must be offered to all couples with male factor infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=see_link\">",
"     \"Donor insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POTENTIAL TREATMENTS IN THE FUTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammalian (mouse) germ cells undergo self-renewal, can be maintained in vitro for several hours, can initiate organized, normal spermatogenesis when transplanted to mice depleted of germ cells due to genetic mutation or after chemotherapy, and can result in normal progeny after successful mating with females [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Successful germ cell transplants can be achieved from mouse to mouse, rat to rat, and rat to immune-compromised mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/100\">",
"     100",
"    </a>",
"    ]. Recently, successful ectopic xenografts of testis from a number of species including primates into mice have allowed studies of drugs and toxicants on spermatogenesis without having to administer the agent to the species [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that germ cell transplantation or cultured testicular stem cells may become a treatment for male infertility and for genetic diseases in men that can be corrected and eradicated in germ cell lines. This possibility raises serious ethical, social, and moral issues [",
"    <a class=\"abstract\" href=\"UTD.htm?3/33/3610/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible future developments include methods of early diagnosis of the underlying causes of male infertility, preventing infertility with early diagnosis and treatment of sexually transmitted genital infections, and identification and avoidance of environmental toxins and medications that may adversely affect reproductive function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"       \"Patient information: Infertility in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"       \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10968799\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment and treatment of the female partner must be initiated for the infertile couple. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Concurrent male and female infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific treatment for male infertility includes dopamine agonists for prolactin-secreting pituitary tumors, and for men with hypogonadotropic hypogonadism, exogenous LH to increase serum and intra-testicular testosterone and, in some cases, exogenous FSH to enhance spermatogenesis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Specific treatment available'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data on the efficacy of varicocele ligation are conflicting. However, it may be useful for young patients with large varicocele and no testicular atrophy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Varicocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assisted reproductive technology is used for the treatment of male infertility in most patients. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Assisted reproductive techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracytoplasmic injection of spermatozoa (ICSI) into the oocyte is the most common technique used for patients with male factor infertility. Pregnancy and live birth rates are similar to natural conception. In non-obstructive azoospermia, testicular sperm extraction (TESE) may harvest adequate number of spermatozoa to achieve fertilization of the oocyte and subsequent pregnancy, even in patients with Klinefelter&rsquo;s syndrome previously considered to be sterile. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intracytoplasmic sperm injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants born after assisted reproductive technology may have low birth weight. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intracytoplasmic sperm injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For couples with chromosomal aneuploidy and Y chromosome microdeletions considering ICSI, we suggest pretreatment counseling on the potential risk of transmitting sex-chromosome aberrations and fertility problems to their offspring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intracytoplasmic sperm injection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/1\">",
"      GUTTMACHER AF. Factors affecting normal expectancy of conception. J Am Med Assoc 1956; 161:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/2\">",
"      de Kretser DM. Male infertility. Lancet 1997; 349:787.",
"     </a>",
"    </li>",
"    <li>",
"     Baker HWG. Male infertility. In: Endocrinology, de Groot LJ (Ed), Saunders, Philadelphia 1994. p.2404.",
"    </li>",
"    <li>",
"     Wang C, Swerdloff RS. Medical treatment of male infertility. In: Infertility Evaluation and Treatment, Keye WR, Chang RJ, Rebar RW, Soules MJ (Eds), Saunders, Philadelphia 1995. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/5\">",
"      World Health Organization. Towards more objectivity in diagnosis and management of male infertility. Int J Androl 1987; 7(Suppl):1.",
"     </a>",
"    </li>",
"    <li>",
"     Baker HWG. Development of clinical trials in male infertility research. In: Perspectives in Andrology, Sario M (Ed), Raven Press, New York 1989. p.367.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/7\">",
"      Schiff JD, Palermo GD, Veeck LL, et al. Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab 2005; 90:6263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/8\">",
"      Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet 2004; 364:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/9\">",
"      Kimura Y, Yanagimachi R. Development of normal mice from oocytes injected with secondary spermatocyte nuclei. Biol Reprod 1995; 53:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/10\">",
"      Yan W, Morozumi K, Zhang J, et al. Birth of mice after intracytoplasmic injection of single purified sperm nuclei and detection of messenger RNAs and MicroRNAs in the sperm nuclei. Biol Reprod 2008; 78:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/11\">",
"      Crowley WF Jr, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res 1985; 41:473.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction, 4th Ed., Cambridge University Press, Cambridge 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/13\">",
"      Eley A, Pacey AA, Galdiero M, et al. Can Chlamydia trachomatis directly damage your sperm? Lancet Infect Dis 2005; 5:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/14\">",
"      Hua VN, Schaeffer AJ. Acute and chronic prostatitis. Med Clin North Am 2004; 88:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/15\">",
"      Bar-Chama N, Goluboff E, Fisch H. Infection and pyospermia in male infertility. Is it really a problem? Urol Clin North Am 1994; 21:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/16\">",
"      Hendry WF, Hughes L, Scammell G, et al. Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. Lancet 1990; 335:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/17\">",
"      The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. World Health Organization. Fertil Steril 1992; 57:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/18\">",
"      Saypol DC, Howards SS, Turner TT, Miller ED Jr. Influence of surgically induced varicocele on testicular blood flow, temperature, and histology in adult rats and dogs. J Clin Invest 1981; 68:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/19\">",
"      Mieusset R, Bujan L, Mondinat C, et al. Association of scrotal hyperthermia with impaired spermatogenesis in infertile men. Fertil Steril 1987; 48:1006.",
"     </a>",
"    </li>",
"    <li>",
"     Hargreave TB. Varicocele: Overview and commentary on the results of the World Health Organization Varicocele Trial. In: Current Advances in Andrology, Waites GMH, Frick J, Baker GWH (Eds), Monduzzi Editore, Salzburg (Austria) 1997. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/21\">",
"      Grasso M, Lania C, Castelli M, et al. Low-grade left varicocele in patients over 30 years old:the effect of spermatic vein ligation on fertility. BJU Int 2000; 85:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/22\">",
"      Unal D, Yeni E, Verit A, Karatas OF. Clomiphene citrate versus varicocelectomy in treatment of subclinical varicocele: a prospective randomized study. Int J Urol 2001; 8:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/23\">",
"      Evers JL, Collins JA. Assessment of efficacy of varicocele repair for male subfertility: a systematic review. Lancet 2003; 361:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/24\">",
"      Kroese AC, de Lange NM, Collins J, Evers JL. Surgery or embolization for varicoceles in subfertile men. Cochrane Database Syst Rev 2012; 10:CD000479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/25\">",
"      Al-Ali BM, Marszalek M, Shamloul R, et al. Clinical parameters and semen analysis in 716 Austrian patients with varicocele. Urology 2010; 75:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/26\">",
"      Kim HH, Goldstein M. Adult varicocele. Curr Opin Urol 2008; 18:608.",
"     </a>",
"    </li>",
"    <li>",
"     White RI. Radiologic management of varicoceles using embolotherapy. In: Management of Impotence and Infertility, Whitehead ED, Nagler HM (Eds), JB Lippincott, Philadelphia 1994. p.228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/28\">",
"      Schlegel PN. Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis. Urology 1997; 49:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/29\">",
"      Meng MV, Greene KL, Turek PJ. Surgery or assisted reproduction? A decision analysis of treatment costs in male infertility. J Urol 2005; 174:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/30\">",
"      Southwick GJ, Temple-Smith PD. Epididymal microsurgery: current techniques and new horizons. Microsurgery 1988; 9:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/31\">",
"      Belker AM, Thomas AJ Jr, Fuchs EF, et al. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991; 145:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/32\">",
"      Meacham RB, Hellerstein DK, Lipshultz LI. Evaluation and treatment of ejaculatory duct obstruction in the infertile male. Fertil Steril 1993; 59:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/33\">",
"      Jarow JP. Transrectal ultrasonography in the diagnosis and management of ejaculatory duct obstruction. J Androl 1996; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/34\">",
"      Silber SJ, Ord T, Balmaceda J, et al. Congenital absence of the vas deferens. The fertilizing capacity of human epididymal sperm. N Engl J Med 1990; 323:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/35\">",
"      Silber SJ, Devroey P, Tournaye H, Van Steirteghem AC. Fertilizing capacity of epididymal and testicular sperm using intracytoplasmic sperm injection (ICSI). Reprod Fertil Dev 1995; 7:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/36\">",
"      Silber SJ, Van Steirteghem AC, Liu J, et al. High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Hum Reprod 1995; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/37\">",
"      Mansour RT, Aboulghar MA, Serour GI, et al. Intracytoplasmic sperm injection using microsurgically retrieved epididymal and testicular sperm. Fertil Steril 1996; 65:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/38\">",
"      Tournaye H, Devroey P, Liu J, et al. Microsurgical epididymal sperm aspiration and intracytoplasmic sperm injection: a new effective approach to infertility as a result of congenital bilateral absence of the vas deferens. Fertil Steril 1994; 61:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/39\">",
"      Silber SJ, Nagy Z, Liu J, et al. The use of epididymal and testicular spermatozoa for intracytoplasmic sperm injection: the genetic implications for male infertility. Hum Reprod 1995; 10:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/40\">",
"      Kolettis PN, Thomas AJ Jr. Vasoepididymostomy for vasectomy reversal: a critical assessment in the era of intracytoplasmic sperm injection. J Urol 1997; 158:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/41\">",
"      Pavlovich CP, Schlegel PN. Fertility options after vasectomy: a cost-effectiveness analysis. Fertil Steril 1997; 67:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/42\">",
"      Robb P, Sandlow JI. Cost-effectiveness of vasectomy reversal. Urol Clin North Am 2009; 36:391.",
"     </a>",
"    </li>",
"    <li>",
"     Wang C, Swerdloff RS. Medical treatment of male infertility. In: Infertility Evaluation and Treatment, Keye WR, Chang RJ, Rebar RW, Soules MJ (Eds), WB Saunders, Philadelphia 1995. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/44\">",
"      Schill WB. Survey of medical therapy in andrology. Int J Androl 1995; 18 Suppl 2:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/45\">",
"      Mesterolone and idiopathic male infertility: a double-blind study. World Health Organization Task Force on the Diagnosis and Treatment of Infertility. Int J Androl 1989; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/46\">",
"      Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; :CD000151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/47\">",
"      A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization. Int J Androl 1992; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/48\">",
"      Foresta C, Bettella A, Garolla A, et al. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/49\">",
"      Attia AM, Al-Inany HG, Farquhar C, Proctor M. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2007; :CD005071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/50\">",
"      Kim HH, Schlegel PN. Endocrine manipulation in male infertility. Urol Clin North Am 2008; 35:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/51\">",
"      Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009; 182:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/52\">",
"      Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/53\">",
"      Kandeel FR, Swerdloff RS. Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception. Fertil Steril 1988; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/54\">",
"      Lue YH, Hikim AP, Swerdloff RS, et al. Single exposure to heat induces stage-specific germ cell apoptosis in rats: role of intratesticular testosterone on stage specificity. Endocrinology 1999; 140:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/55\">",
"      Wang C, McDonald V, Leung A, et al. Effect of increased scrotal temperature on sperm production in normal men. Fertil Steril 1997; 68:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/56\">",
"      Munkelwitz R, Gilbert BR. Are boxer shorts really better? A critical analysis of the role of underwear type in male subfertility. J Urol 1998; 160:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/57\">",
"      Oldereid NB, Rui H, Purvis K. Life styles of men in barren couples and their relationship to sperm quality. Int J Fertil 1992; 37:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/58\">",
"      Schlegel PN, Girardi SK. Clinical review 87: In vitro fertilization for male factor infertility. J Clin Endocrinol Metab 1997; 82:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/59\">",
"      Khorram O, Patrizio P, Wang C, Swerdloff R. Reproductive technologies for male infertility. J Clin Endocrinol Metab 2001; 86:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/60\">",
"      Boomsma CM, Heineman MJ, Cohlen BJ, Farquhar C. Semen preparation techniques for intrauterine insemination. Cochrane Database Syst Rev 2004; :CD004507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/61\">",
"      Hughes EG, Collins JP, Garner PR. Homologous artificial insemination for oligoasthenospermia: a randomized controlled study comparing intracervical and intrauterine techniques. Fertil Steril 1987; 48:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/62\">",
"      Ho PC, Poon IM, Chan SY, Wang C. Intrauterine insemination is not useful in oligoasthenospermia. Fertil Steril 1989; 51:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/63\">",
"      Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/64\">",
"      Van Steirteghem AC, Liu J, Joris H, et al. Higher success rate by intracytoplasmic sperm injection than by subzonal insemination. Report of a second series of 300 consecutive treatment cycles. Hum Reprod 1993; 8:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/65\">",
"      Van Steirteghem AC, Nagy Z, Joris H, et al. High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod 1993; 8:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/66\">",
"      Palermo GD, Schlegel PN, Sills ES, et al. Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter's syndrome. N Engl J Med 1998; 338:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/67\">",
"      Reubinoff BE, Abeliovich D, Werner M, et al. A birth in non-mosaic Klinefelter's syndrome after testicular fine needle aspiration, intracytoplasmic sperm injection and preimplantation genetic diagnosis. Hum Reprod 1998; 13:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/68\">",
"      Staessen C, Tournaye H, Van Assche E, et al. PGD in 47,XXY Klinefelter's syndrome patients. Hum Reprod Update 2003; 9:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/69\">",
"      Palermo GD, Cohen J, Alikani M, et al. Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility. Fertil Steril 1995; 63:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/70\">",
"      Tariatzis, BC, Bili, H. Intracytoplasmic sperm injection. Survey of world results. Ann NY Acad Sci, 2000; 900:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/71\">",
"      Gnoth C, Maxrath B, Skonieczny T, et al. Final ART success rates: a 10 years survey. Hum Reprod 2011; 26:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/72\">",
"      Tournaye H, Camus M, Goossens A, et al. Recent concepts in the management of infertility because of non-obstructive azoospermia. Hum Reprod 1995; 10 Suppl 1:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/73\">",
"      Schlegel PN, Palermo GD, Goldstein M, et al. Testicular sperm extraction with intracytoplasmic sperm injection for nonobstructive azoospermia. Urology 1997; 49:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/74\">",
"      Tesarik J, Mendoza C, Testart J. Viable embryos from injection of round spermatids into oocytes. N Engl J Med 1995; 333:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/75\">",
"      Al-Hasani S, Ludwig M, Palermo I, et al. Intracytoplasmic injection of round and elongated spermatids from azoospermic patients: results and review. Hum Reprod 1999; 14 Suppl 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/76\">",
"      Silber SJ, van Steirteghem A, Nagy Z, et al. Normal pregnancies resulting from testicular sperm extraction and intracytoplasmic sperm injection for azoospermia due to maturation arrest. Fertil Steril 1996; 66:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/77\">",
"      Chen SU, Ho HN, Chen HF, et al. Fertilization and embryo cleavage after intracytoplasmic spermatid injection in an obstructive azoospermic patient with defective spermiogenesis. Fertil Steril 1996; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/78\">",
"      Mulhall JP, Reijo R, Alagappan R, et al. Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection. Hum Reprod 1997; 12:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/79\">",
"      Tournaye H, Staessen C, Liebaers I, et al. Testicular sperm recovery in nine 47,XXY Klinefelter patients. Hum Reprod 1996; 11:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/80\">",
"      Chan PT, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/81\">",
"      Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002; 20:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/82\">",
"      Revel A, Haimov-Kochman R, Porat A, et al. In vitro fertilization-intracytoplasmic sperm injection success rates with cryopreserved sperm from patients with malignant disease. Fertil Steril 2005; 84:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/83\">",
"      Woldringh GH, Kremer JA, Braat DD, Meuleman EJ. Intracytoplasmic sperm injection: a review of risks and complications. BJU Int 2005; 96:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/84\">",
"      Bonduelle M, Camus M, De Vos A, et al. Seven years of intracytoplasmic sperm injection and follow-up of 1987 subsequent children. Hum Reprod 1999; 14 Suppl 1:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/85\">",
"      Palermo GD, Colombero LT, Schattman GL, et al. Evolution of pregnancies and initial follow-up of newborns delivered after intracytoplasmic sperm injection. JAMA 1996; 276:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/86\">",
"      Sutcliffe AG, Taylor B, Saunders K, et al. Outcome in the second year of life after in-vitro fertilisation by intracytoplasmic sperm injection: a UK case-control study. Lancet 2001; 357:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/87\">",
"      Wennerholm UB, Bergh C, Hamberger L, et al. Incidence of congenital malformations in children born after ICSI. Hum Reprod 2000; 15:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/88\">",
"      Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002; 346:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/89\">",
"      Schieve LA, Meikle SF, Ferre C, et al. Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med 2002; 346:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/90\">",
"      Helmerhorst FM, Perquin DA, Donker D, Keirse MJ. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ 2004; 328:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/91\">",
"      Bhattacharya S, Hamilton MP, Shaaban M, et al. Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial. Lancet 2001; 357:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/92\">",
"      Donoso P, Tournaye H, Devroey P. Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review. Hum Reprod Update 2007; 13:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/93\">",
"      Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med 2009; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/94\">",
"      Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/95\">",
"      Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/96\">",
"      Hsiao W, Stahl PJ, Osterberg EC, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol 2011; 29:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/97\">",
"      Kovacs GT, Mushin D, Kane H, Baker HW. A controlled study of the psycho-social development of children conceived following insemination with donor semen. Hum Reprod 1993; 8:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/98\">",
"      Brinster RL, Avarbock MR. Germline transmission of donor haplotype following spermatogonial transplantation. Proc Natl Acad Sci U S A 1994; 91:11303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/99\">",
"      Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci U S A 1994; 91:11298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/100\">",
"      Clouthier DE, Avarbock MR, Maika SD, et al. Rat spermatogenesis in mouse testis. Nature 1996; 381:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/101\">",
"      Dobrinski I. Germ cell transplantation. Semin Reprod Med 2005; 23:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/102\">",
"      Dym M. Spermatogonial stem cells of the testis. Proc Natl Acad Sci U S A 1994; 91:11287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/103\">",
"      Wivel NA, Walters L. Germ-line gene modification and disease prevention: some medical and ethical perspectives. Science 1993; 262:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/33/3610/abstract/104\">",
"      Schlatt S, Ehmcke J, Jahnukainen K. Testicular stem cells for fertility preservation: preclinical studies on male germ cell transplantation and testicular grafting. Pediatr Blood Cancer 2009; 53:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7452 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3610=[""].join("\n");
var outline_f3_33_3610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10968799\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Concurrent male and female infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Use of assisted reproductive techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Documentation of treatment efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LIMITED AVAILABLE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPECIFIC TREATMENT AVAILABLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypogonadotropic hypogonadism due to hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypogonadotropic hypogonadism due to other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF UNCERTAIN EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genital infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sperm autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Retrograde ejaculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Varicocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Obstructive azoospermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EMPIRICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ASSISTED REPRODUCTIVE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Retrieval of sperm from the testis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Artificial insemination with donor semen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POTENTIAL TREATMENTS IN THE FUTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10968799\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7452|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/24/11661\" title=\"figure 1\">",
"      Fecundability in healthy couples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7452|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/23/11645\" title=\"table 1\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/55/37755\" title=\"table 2\">",
"      Male infertility no treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/34/20011\" title=\"table 3\">",
"      Male infertility possible Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/30/1516\" title=\"table 4\">",
"      Male infertility unproven Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=related_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=related_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=related_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_33_3611="Polio eradication";
var content_f3_33_3611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Four pillars of polio eradication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         1.",
"        </strong>",
"        Achieving a high level of coverage with at least 3 doses of the oral poliovirus vaccine (OPV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2.",
"        </strong>",
"        Providing supplementary doses of OPV to all children less than 5 years old during national immunization days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3.",
"        </strong>",
"        Surveillance for all cases of acute flaccid paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         4.",
"        </strong>",
"        House-to-house OPV campaigns, targeting areas in which transmission of wild poliovirus persists, based on surveillance studies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3611=[""].join("\n");
var outline_f3_33_3611=null;
var title_f3_33_3612="Pretreat risk stratify prost CA";
var content_f3_33_3612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretreatment risk stratification for prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gleason score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum PSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Standard risk groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-risk",
"       </td>",
"       <td>",
"        T1c-T2a",
"       </td>",
"       <td>",
"        &le;6",
"       </td>",
"       <td>",
"        &lt;10 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermediate-risk",
"       </td>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10 to 20 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-risk",
"       </td>",
"       <td>",
"        T2c",
"       </td>",
"       <td>",
"        8 to 10",
"       </td>",
"       <td>",
"        &gt;20 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Risk groupings used by Memorial Sloan-Kettering and Seattle groups",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-risk",
"       </td>",
"       <td>",
"        &le;T2a",
"       </td>",
"       <td>",
"        &le;6",
"       </td>",
"       <td>",
"        &lt;10 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermediate-risk",
"       </td>",
"       <td colspan=\"3\">",
"        One elevated risk factor:",
"        <br/>",
"        Clinical stage &ge;T2a disease, Gleason score &ge;7, PSA &ge;10 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-risk",
"       </td>",
"       <td colspan=\"3\">",
"        Two elevated risk factors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T1c: tumor identified by needle biopsy (eg, because of elevated PSA); T2a: tumor involves one-half of one lobe or less; T2b: tumor involves more than one-half of one lobe but not both lobes; T2c: tumor involving both lobes.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Zelefsky M, et al. Int J Radiat Oncol Biol Phys 2000; 47:1261.",
"      </li>",
"      <li>",
"       Blasko J, et al. Int J Radiat Oncol Biol Phys 2000; 48:111.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3612=[""].join("\n");
var outline_f3_33_3612=null;
var title_f3_33_3613="Perinatal autopsy procedure";
var content_f3_33_3613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detailed procedure for perinatal autopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hints for dissection of the intact fetus:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Make generous incisions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Examine organs in situ before evisceration - photograph any anomalies and pertinent negative findings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Remove and set aside the thymus and gonads before evisceration because they are small and often difficult to find after dissection.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Place the brain into a large, preweighed vessel filled with fixative. Weigh the vessel with the fixative and brain to determine brain weight.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. After each organ is removed, compare the organ weight with standards.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Dissect the heart and great vessels with the descending aorta and lungs after fixation. Document venous return and the ductus arteriosus before dissecting the heart off of the lungs. When opening the heart, open the appendage side from the inferior to the superior vena cava and look immediately for the foramen ovale and the coronary sinus. Probe the coronary sinus to document whether there is a persistent left superior vena cava. Open the right heart along the lines of flow and continue through the main pulmonary artery through the ductus arteriosus and into the descending aorta. Open the left atrium between the left and right pulmonary veins, and then open right ventricle on the posterior descending coronary and up along the left anterior descending artery and out the aorta. This will put the papillary muscles on the free wall, give a clean view of the septum (easy to see common ventricular septal defects this way), and maintains the mitral valve intact. Examine carefully for number of valve leaflets in the great vessels.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Procedure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Proper respect for the fetus should be maintained during the procedure. Eviscerate by using the classic \"Y\" shaped incision. Reflect back the skin, remove the chest plate after cutting through the soft ribs and clavicle. Obtain lung tissue for microbiology. Examine the organs in situ for any situs malformations, ensure all organs are present, and look for any malformations (photograph abnormalities in situ, if identified).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Remove and weight the thymus, process. Identify gonads, remove, and process. Bluntly dissect up though the neck to the tongue (above the larynx at a minimum), remove as a block from the tongue to anus. Once removed, use a thin probe to document tracheal and esophageal patency (examine for tracheoesophageal fistulas).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; The organ bloc can be dissected fresh or fixed overnight if tissues are autolyzed. Before tissues are fixed, obtain fresh tissue if needed for special studies. Remove and save the vertebral column. Remove the brain and spinal cord, eyes (intracranially), and pituitary. The brain and spinal cord is best be removed by a dorsal approach, which is especially useful in identifying spina bifida and in cases with meningocele, meningomyelocele and other neural tube defects.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; After the scalp is reflected, the cranium can be opened along suture lines. It is sometimes helpful to keep the dura intact. By cradling the head and holding it over a preweighed vessel filled with fixative, the fetal brain can be allowed to fall slowly into the fixative while the cranial vessels and tentoriums are cut. A deep cut into the spinal canal will allow the brain to \"slip\" into the fixative. Fetal and infantile brains contains more water than adult brains and can therefore be floated in formalin more concentrated than 10 percent. This is achieved by adding undiluted formalin to the formalin solution slowly until the brain floats; thereby avoiding distortion due to fixation. As the brain is being fixed over the following two to three days, it will attain the same density as the formalin and sink. By then, the sunken brain will not distort further and it will not be necessary to add additional formalin. The body should be stitched closed. It is best to ensure the body is presentable. Fetuses who will be buried are rarely embalmed.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3613=[""].join("\n");
var outline_f3_33_3613=null;
var title_f3_33_3614="HCW prophylaxis recs I";
var content_f3_33_3614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82359%7EID%2F60692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82359%7EID%2F60692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postexposure prophylaxis for vaccine preventable diseases in healthcare workers - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Definition of",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Prophylaxis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Work restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Susceptible",
"       </td>",
"       <td class=\"subtitle2\">",
"        Exposed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Hepatitis B",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Never or incompletely vaccinated and never had an anti-HBs titer &gt;10 IU/mL",
"       </td>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - known HBsAg positive",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - HBIG 0.06 mL/kg x1 and initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder",
"         </strong>",
"         - HBIG x2 Response unknown - test healthcare worker; HBIG x1 if not protected and boost or complete vaccination",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        <p>",
"         <strong>",
"          Acute infection",
"         </strong>",
"         - relieve from direct patient contact until jaundice resolves;",
"        </p>",
"        <p>",
"         <strong>",
"          Chronic infection",
"         </strong>",
"         - counsel healthcare worker on infection control practices - if transmission occurs, restrict from invasive procedures and direct contact with patient equipment until hepatitis B antigenemia resolves",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - known HBsAg negative",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - Initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder or response unknown",
"         </strong>",
"         - no treatment needed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - unknown HBsAg",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder",
"         </strong>",
"         - treat as HBsAg positive if high risk source",
"        </p>",
"        <p>",
"         <strong>",
"          Response unknown",
"         </strong>",
"         - test healthcare worker; if not protected complete vaccination or begin revaccination.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"       </td>",
"       <td>",
"        Did not recieve annual immunization",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face to face contact in open area",
"       </td>",
"       <td>",
"        Catch-up immunization and consider amantidine or rimantidine 100 mg PO BID or oseltamivir 75 mg PO QD or BID",
"       </td>",
"       <td>",
"        Relieve from care of high risk patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measles",
"       </td>",
"       <td>",
"        None of the following - documentation of diagnosis of measles by a physician, serologic evidence of immunity, two doses of MMR",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face to face in open area",
"       </td>",
"       <td>",
"        Measles vaccine if no contraindications or immune globulin 0.25 mL/kg (maximum 15 mL) within 6 days or exposure",
"       </td>",
"       <td>",
"        Furlough from health-care facility until 4 days after rash appears or from day 5 after first exposure to day 21 after last exposure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postexposure prophylaxis for vaccine-preventable diseases in health care workers - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Definition of",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prophylaxis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Work restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Susceptible",
"       </td>",
"       <td class=\"subtitle2\">",
"        Exposed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella zoster",
"       </td>",
"       <td>",
"        None of the following: history of varicella, serologic evidence of immunity, two doses of varicella vaccine",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face-to-face contact in open area with a patient who has active lesions or in the 48 hours before onset of primary infection",
"       </td>",
"       <td>",
"        Varicella zoster immune globulin (125 U/10 kg intramuscularly) for immunocompromised or pregnant health care workers or varicella vaccine if no contraindications",
"       </td>",
"       <td>",
"        Furlough from health care facility until all lesions are dry and crusted or from day 8 after first exposure to day 21 after last exposure (extend to day 28 if VZIG given)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A",
"       </td>",
"       <td>",
"        None of the following: history of hepatitis A, serologic evidence of immunity, two doses of hepatitis A vaccine",
"       </td>",
"       <td>",
"        Ingestion of contaminated food, contact with feces from a patient infected with hepatitis A",
"       </td>",
"       <td>",
"        Immune globulin 0.02 mL/kg&nbsp;intramuscularly in gluteal or deltoid within 14 days of exposure; consider concurrent hepatitis A vaccination",
"       </td>",
"       <td>",
"        Relieve from direct patient contact and food handling until&nbsp;seven days after onset of jaundice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pertussis",
"       </td>",
"       <td>",
"        All health care workers",
"       </td>",
"       <td>",
"        Direct contact with respiratory secretions or droplets from infected person",
"       </td>",
"       <td>",
"        <p>",
"         Azithromycin&nbsp;500 mg&nbsp;orally&nbsp;on day one followed by 250 mg&nbsp;orally&nbsp;daily&nbsp;on days two to five (trimethoprim-sulfamethoxazole is an alternative)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Active disease or symptomatic postexposure",
"         </strong>",
"         - furlough from health care facility from beginning of catarrhal stage to&nbsp;third week after onset of paroxysms or&nbsp;five days after effective therapy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Asymptomatic postexposure",
"         </strong>",
"         - no restriction providing antibiotic therapy is taken",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria meningitidis",
"       </td>",
"       <td>",
"        All health care workers",
"       </td>",
"       <td>",
"        Direct contact with respiratory secretions from infected person",
"       </td>",
"       <td>",
"        Ciprofloxacin 500 mg&nbsp;orally x 1 or ceftriaxone 250 mg&nbsp;intramuscularly x 1 or rifampin 600 mg&nbsp;orally&nbsp;twice daily&nbsp;for&nbsp;two&nbsp;days",
"       </td>",
"       <td>",
"        No restriction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3614=[""].join("\n");
var outline_f3_33_3614=null;
var title_f3_33_3615="Finger trap fixture";
var content_f3_33_3615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Finger trap fixture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Regardless of whether they are used in reduction, finger traps are a useful adjunct before the procedure. Traction is applied by attaching the finger traps to the thumb, index, and middle fingers, while keeping the elbow flexed at 90 degrees and the forearm in neutral rotation. Downward traction, using weights, is placed on the distal humerus for at least five minutes before any reduction attempt. This enables muscular relaxation and helps distract the fracture fragments, bringing the radius closer to normal length.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_33_3615=[""].join("\n");
var outline_f3_33_3615=null;
